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ABSTRACT
VALPROIC ACID DISRUPTS PRIMITIVE HEMATOPOIESIS IN XENOPUS LAEVIS
THROUGH THE INHIBITION OF HISTONE DEACETYLASE 3.
Rishita Shah
Peter Klein

Histone deacetylases (HDACs) are important regulators of developmental processes
and cellular functions. However, their role in hematopoiesis has not been determined,
and in Xenopus laevis, a specific function for HDACs has yet to be identified.
In the present work, we employed the class I selective HDAC inhibitor, valproic acid
(VPA), to identify hdac3 as an essential mediator of primitive hematopoiesis. Exposure
to VPA during gastrulation results in a marked and specific block of primitive
hematopoiesis in Xenopus embryos. Furthermore, pharmacological and loss of function
studies demonstrate that hdac3 functions downstream of bmp4 signaling and is
specifically required for primitive erythropoiesis. We also describe here that runx1 is
activated by bmp4 in an HDAC-dependent manner. Consistent with this, restoring runx1
expression partially rescues VPA mediated hematopoietic defects. We further identify
that the effects of HDAC inhibition on primitive hematopoiesis is conserved in mammals,
as yolk sac hematopoiesis in mouse is also blocked with exposure to VPA. Lastly, we
identify a bicarbonate transporter as the primary means for VPA to enter the embryos.
Our findings demonstrate for the first time a critical role for hdac3 in primitive
hematopoiesis, and indicate that specific developmental defects associated with
exposure to VPA, a significant teratogen in humans, arise through inhibition of class I
HDACs.
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1. CHAPTER I: INTRODUCTION
1.1 Vertebrate Hematopoiesis
In almost all vertebrate species, including mammals, amphibians, birds and fish,
blood development occurs in two phases, primitive and definitive hematopoiesis.
Primitive, or embryonic, hematopoiesis, usually occurs outside of the embryo, and gives
rise to erythrocytes and primitive vessels responsible for transporting nutrients to the
growing embryo. Conventionally, primitive hematopoiesis refers to the development of
embryonic erythroid cells, as they are the predominant cell type arising from this
process. However, recently small populations of megakaryocytes and macrophages
have also been observed during early embryonic hematopoiesis (Bennett et al., 2001;
Tober et al., 2007). Vertebrate primitive erythrocytes are larger than their adult
counterparts and retain their nucleus (Palis et al., 2010; Zon and Peterson, 2005).
Importantly, cells formed during primitive hematopoiesis are transient and have a finite
number of cell divisions before terminally differentiating. In contrast, definitive, or adult,
hematopoiesis functions in a long-term capacity by creating self-renewing hematopoietic
stem cells (HSCs) which function to provide the developed organism with all mature
hematopoietic lineages for the lifetime of the animal.
1.1.1 Primitive Hematopoiesis
In the majority of amphibians and fish, generation of primitive blood occurs from
within the embryo. In Xenopus laevis, this structure is known as the ventral blood island
(VBI), a mesodermal tissue located ventrally along the anterior-posterior axis. The VBI is
derived from two regions of presumptive mesoderm that contribute to anterior and
posterior domains (aVBI and pVBI) (Ciau-Uitz et al., 2000) (Figure 1.1 A).
1

rimitive hematopoiesis. (A) Schematic of embryonic origins of anterior
Figure 1.1 Primitive
and posterior VBI in Xenopus. The anterior VBI (blue) is derived from dorsal
blastomeres, and the posterior VBI (green) is derived from the ventral side of the
embryo. Adapted from (Ciau
(Ciau-Uitz et al., 2010; Ciau-Uitz et al., 2000). (B)) Mammalian
M
primitive hematopoiesis. T
The blood islands develop at E7.5 where
here the extraembryonic
mesoderm (EM) meets
ts the visceral endoderm (VE). C
Circulating
ulating red blood cells appear at
E10.5 in the extraembryonic yolk sac (YS). Adapted from (Sadlon et al., 2004; Tracey
and Speck, 2000).
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The aVBI originates from blastomeres located in the dorsal marginal zone (Ciau-Uitz et
al., 2000; Tracey et al., 1998). During gastrulation, these cells migrate across the top of
the blastula and move to a ventral-anterior position, just posterior to the cement gland
(Kumano et al., 1999; Walmsley et al., 2002; Walmsley et al., 2008). The interaction of
the migrating mesoderm and the overlying ectoderm is critical as several signaling
molecules originating from the ectoderm, such as bmp4 and gata2 are necessary for
primitive hematopoietic specification (Dalgin et al., 2007). The precursor cells of the
aVBI are detected during late neurulation (stage 17) and co-express both hematopoietic
(runx1, gata2, scl) and endothelial (xhex, xfli) markers (Walmsley et al., 2002). At the
end of neurulation, the aVBI begins to differentiate into separate lineages, giving rise
predominantly to myeloid cells, but also erythroid and vascular cells (Costa et al., 2008;
Smith et al., 2002; Tashiro et al., 2006; Walmsley et al., 2002). In contrast, the pVBI
predominantly forms primitive erythrocytes, and a small population of leukocytes and
lymphoid cells (Ciau-Uitz et al., 2010). Also distinct from the dorsally derived aVBI, the
pVBI is of ventral origin (Ciau-Uitz et al., 2000). Markers of the pVBI are not detectable
until much later in development, during tailbud stages, after aVBI expression has already
commenced (Tashiro et al., 2006; Walmsley et al., 2008). While vasculature also derives
from the pVBI, no common progenitor for erythroid and endothelial cells in the pVBI has
been discovered yet. Both VBI compartments are specified during gastrulation, although
markers of hematopoietic lineages are not detectable until early tailbud stages (Kumano
et al., 1999; Walmsley et al., 2002).
Similarly, in zebrafish, primitive hematopoiesis also occurs at two distinct sites,
the rostral blood island (RBI), and the intermediate cell mass (ICM) (de Jong and Zon,
2005). Zebrafish anterior and posterior lateral plate mesoderm (ALM and PLM
3

respectively) exist as bilateral stripes and begin to express scl, an early hematopoietic
marker, at 10 hpf. The two stripes of the PLM move medially and merge around 18 hpf
to form the ICM (Chen and Zon, 2009). The ICM gives rise to erythrocytes and
endothelial cells, similarly to the pVBI in Xenopus. Like the aVBI, cells from the RBI/ALM
region predominantly differentiate into macrophages, but also express markers for
endothelial and erythroid lineages (de Jong and Zon, 2005). Interestingly, zebrafish
have a third site of hematopoiesis, the posterior blood island which supplies the embryo
with erythrocytes during the transition from primitive to definitive hematopoiesis
(Bertrand et al., 2007). No such intermediate hematopoietic source has been discovered
in other organisms.
Unlike zebrafish and Xenopus, mammalian and avian primitive hematopoiesis
occurs outside of the embryo in the extraembryonic yolk sac (Figure 1.1 B). In mice and
humans, the first blood islands, small mesodermal clusters containing both
hematopoietic and vascular cells, are visualized around E7.5 in mouse and day 18.5 in
human (Palis et al., 2010; Takashina, 1987). Similar to Xenopus, the specification of
erythroblasts in mouse occurs during gastrulation at E7.25, before the blood islands
appear (Palis et al., 1999).
1.1.2 Hemangioblast
Common to all of these organisms, primitive blood and endothelial cells are
thought to derive from the same structure and develop simultaneously from a progenitor
population known as the hemangioblast (Sabin, 1920). Correlative data from zebrafish
lateral plate mesoderm, which contains cells that co-express both hematopoietic (scl,
lmo, gata2) and vascular (fli1, flk1) markers, supports this hypothesis (Dooley et al.,
2005). Similarly, mouse yolk sacs develop both hematopoietic and angiogenic structures
4

in close proximity to one another, suggesting a common progenitor (Silver and Palis,
1997). The first direct evidence for a hemangioblast structure was shown using clonal
analysis from gastrulating mouse embryos. Mesodermal cells within the primitive streak
which co-express flk-1 and brachyury give rise to colonies expressing hematopoietic,
endothelial, and vascular smooth muscle markers, suggesting a single progenitor with
potential to form all three cell types (Keller, 2004). The first in vivo example of a
hemangioblast was demonstrated with single-cell fate mapping in zebrafish. By labeling
individual cells in the ventral mesoderm of shield stage (6hpf) zebrafish embryos, Vogeli
et al demonstrated that a small population of progenitor cells can give rise to both
hematopoietic and endothelial lineages. Interestingly, in both mouse and zebrafish, cells
derived from the hemangioblast do not account for all hematopoietic and endothelial
lineages, suggesting that progeny of hemangioblastic precursors may have a specialized
role during embryonic hematopoiesis (Vogeli et al., 2006). In Xenopus, co-expression of
angiogenic and hematopoietic markers in the cells of the presumptive aVBI suggest the
existence of a hemangioblast-like structure (Walmsley et al., 2002). This is supported by
the fact that cells of the aVBI only account for a small population of differentiated
hematopoietic and endothelial cells, since the majority of primitive RBCs are derived
from the pVBI, which also has an independently derived population of endothelial cells.
While this evidence follows patterns observed in mice and fish, a functional
hemangioblast population has yet to be identified in Xenopus (Ciau-Uitz et al., 2000).
1.1.3 Definitive Hematopoiesis
The second phase of blood development, definitive hematopoiesis, generates all
adult hematopoietic lineages. A critical step during the onset of definitive hematopoiesis
is the generation of HSCs. In Xenopus, definitive hematopoietic cells originate from the
5

dorsal lateral plate mesoderm (DLP) during tailbud stages (Turpen, 1998). One of the
primary roles of the DLP in HSC generation is its contribution to the development of the
trunk dorsal aorta (DA). Transplant and ablation studies demonstrate that the DA is
made up of migrating cells originating from the DLP, and that removal of the DLP
prevents formation of the DA (Cleaver and Krieg, 1998; Shibata et al., 2008). In the
Xenopus DA, cells expressing the hematopoietic markers scl, gata2, and runx1 are
found in small clusters on the ventral side of the trunk DA (Ciau-Uitz et al., 2000). These
cells are thought to represent the first emerging adult HSCs in the embryo. Similar
observations in mouse and zebrafish support this hypothesis. Mammalian definitive
blood is derived from a region known as the aorta-gonad-mesonephros (AGM), which
develops around E10 (Medvinsky and Dzierzak, 1996). Specifically, the aorta portion of
the AGM is sufficient to repopulate multiple lineages in adult recipients, demonstrating its
ability to establish a self-renewing population of HSC (de Bruijn et al., 2000). The gonad
and mesonephros regions do not possess this capability until later in development,
suggesting that the HSCs originate in the aorta and subsequently develop in the
remainder of the AGM (de Bruijn et al., 2000). In zebrafish, a structure analogous to the
AGM exists near the axial vein, and the first definitive HSCs are derived from the DA
(Kissa and Herbomel, 2010). Common to all three systems are the hematopoietic
clusters associated with the ventral wall of the DA. This has led to a hypothesis that
definitive HSCs transdifferentiate from the endothelial cells of the DA itself, referred to as
a hemogenic endothelium (Lancrin et al., 2010). Studies in mice using lineage tracing
and explant experiments demonstrate the progression of mesodermal cells to
hematopoietic progenitors via an endothelial intermediate (Boisset and Robin; Eilken et
al., 2009; Zovein et al., 2008). Corroborating data are observed in zebrafish; whole
6

embryo live imaging demonstrates budding of DA endothelial cells into the surrounding
vasculature where they differentiate into HSCs and generate adult hematopoietic cells
(Bertrand et al.; Kissa and Herbomel, 2010; Lam et al., 2010).
1.1.4 BMP
Bone morphogenetic proteins (BMPs), part of the TGF-beta superfamily, are
crucial to vertebrate hematopoiesis (Soderberg et al., 2009). Of the fourteen known BMP
family members, bmp4 is the best characterized in blood development (Soderberg et al.,
2009). Bmp4 signaling takes place through serine/ threonine kinase receptors and
downstream effectors Smads 1, 5 and 8 (Larsson and Karlsson, 2005) (Figure 1.2).
Overexpression of bmp4 in Xenopus results in an expansion of the VBI (Maeno et al.,
1996). Exogenous bmp4 induces globin expressing blood cells in mouse embryoid
bodies and Xenopus ectodermal explants (Hemmati-Brivanlou and Thomsen, 1995;
Johansson and Wiles, 1995). Bmp4-null mouse embryos die early during development
due to severe defects in mesoderm formation (Winnier et al., 1995). The few embryos
that survive have a severe loss of primitive blood in the yolk sac blood islands and
developing circulation (Winnier et al., 1995). Similarly, in Xenopus, inhibition of bmp
signaling by injection of dominant negative bmp receptors prevents primitive
hematopoiesis (Kumano et al., 1999; Maeno et al., 1996; Paik and Zon; Walmsley et al.,
2002).
Several studies involving smad1 and smad5, downstream effectors of bmp4,
demonstrate their essential role in primitive hematopoiesis. Mouse embryoid bodies (EB)
lacking smad5 have defects in generating erythroid progenitor colony forming cells
(EryP-CFC) (Liu et al., 2003).

7

Figure 1.2 BMP signaling pathway. From (Yamaguchi et al., 2000).
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Similarly, smad1 null EBs do not generate EryP-CFS, and overexpression of smad1 in
EB causes an increase in erythroid progenitors (Cook et al., 2011; Zafonte et al., 2007).
Interestingly, this only occurs if smad1 expression is altered before erythroid
specification. After hemangioblast commitment, smad1 reverses roles and inhibits
formation of erythroid progenitors (Cook et al., 2011; Zafonte et al., 2007). Similarly in
zebrafish, splicing defects in smad1 and smad5, which result in nonfunctional protein,
inhibit primitive hematopoiesis (Tao et al., 2009). Zebrafish embryos lacking smad5 have
a decrease in circulating RBCs, but interestingly, smad1 morphants have a defect in
myelopoiesis and not erythropoiesis, suggesting divergent roles downstream of bmp4 to
regulate zebrafish primitive hematopoiesis (McReynolds et al., 2007; Mullins et al.,
1996). This dual role for smads has not been observed in Xenopus. An inducible form of
smad6, a bmp signaling antagonist, expressed after gastrulation prevents formation of
the VBI; notably, this can be rescued by overexpression of smad1 (Schmerer and
Evans, 2003). As bmp signaling is important for hematopoietic specification, it regulates
expression of several hematopoietic transcription factors, including gata1, gata2, scl and
lmo2, described below (Mead et al., 2001; Mead et al., 1998) (Figure 1.3).
1.1.5 Gata1 and Gata2
Two downstream targets of bmp4 signaling, gata1 and gata2, are indispensible
for vertebrate hematopoiesis. Both gata proteins are transcription factors that function to
regulate primitive and definitive hematopoiesis (Shimizu et al., 2001; Tsai et al., 1994).
gata1 and gata2 null mice die early in development due to a lack of primitive
erythropoiesis (Fujiwara et al., 1996; Tsai et al., 1994). Gata1 null ES cells fail to
produce fully differentiated primitive and definitive RBCs, and gata2 haploid mice have

9

Figure 1.3 BMP signaling pathway during hematopoiesis. Adapted from (Sadlon et
al., 2004).
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compromised HSC proliferation (Rodrigues et al., 2005; Weiss et al., 1994). These
observations suggest distinct temporal requirements for each gene; gata2 is important
for maintenance of hematopoietic progenitors, both primitive and definitive, and gata1 is
required for terminal differentiation of erythroid cells (Patient and McGhee, 2002). This is
supported by the fact that as an erythroblast matures, gata2 expression decreases
(Patient and McGhee, 2002). Mice lacking both gata1 and gata2 show a complete
absence of yolk sac erythropoiesis, and definitive hematopoiesis is also significantly
compromised, but loss of individual proteins does not have as dramatic of an effect,
suggesting that gata1 and gata2 also share some functional redundancy, especially
during primitive hematopoiesis (Fujiwara et al., 2004).
Interestingly, both gata1 and gata2 are sufficient to induce globin in Xenopus
ectodermal explants, suggesting that in Xenopus, the functions of these gatas may
overlap even more than their mammalian counterparts (Dalgin et al., 2007; Mead et al.,
2001). In Xenopus, both gata1 and gata2 are induced by expression of bmp4, although
direct activation has only been shown for gata2 (Friedle and Knochel, 2002; Zhang and
Evans, 1996). Additionally, bmp-mediated gata2 expression is attenuated by expression
of fgf (Xu et al., 1999). Gata1, scl and lmo2 function in a complex to regulate primitive
hematopoiesis in Xenopus, since ectopic expression of all three transcription factors
expands the VBI (Mead et al., 2001).
1.1.6 Runx1
Exceptionally, runx1 is one of the few hematopoietic transcription factors whose
function is not conserved between amphibians and mammals. In Xenopus, runx1 is
necessary for primitive hematopoiesis, but in mice, runx1 predominantly functions in
adult hematopoiesis and HSC generation (Speck and Gilliland, 2002; Tracey et al.,
11

1998). Overexpression of a dominant negative form of runx1 in Xenopus completely
blocks primitive RBC formation (Tracey et al., 1998). In contrast, runx1 null mice still
develop primitive RBCs, although with abnormal morphology, and die at E12.5 due to an
absence of definitive hematopoietic lineages (Okuda et al., 1996; Wang et al., 1996;
Yokomizo et al., 2008). Also, tissue specific deletion of runx1 prevents hematopoietic
clusters and HSC formation in the DA, suggesting a strong requirement for runx1 in the
development of the hemogenic endothelium (Chen et al., 2009; North et al., 1999;
Yokomizo et al., 2001). Interestingly, zebrafish runx1 has a dual role, as knockdown of
runx1 with antisense morpholino reduces circulating primitive RBCs, and blocks
definitive hematopoiesis in the DA (Kalev-Zylinska et al., 2002).
While very little is known about the role of runx1 in primitive hematopoiesis, its
function and regulation is under extensive study in mouse HSC generation. Runx1
interacts with gata2 and scl to regulate smad6 expression in the AGM, by upregulating
its expression in a negative feedback loop (Knezevic et al.). There is some evidence that
runx1 regulates gata1 expression, since runx1 null mouse embryos have reduced
expression of gata1 in primitive erythrocytes (Yokomizo et al., 2008). Also, smad1 can
transactivate runx1 promoter and enhance runx1 reporter activity in-vitro, but no
evidence of runx1 activation by bmp4 has been demonstrated in Xenopus (Pimanda et
al., 2007).
1.1.7 Scl and Lmo2
Stem cell leukemia (scl), also called tal1, is a conserved transcription factor
essential for hematopoiesis in all vertebrates. Scl is expressed in both the endothelial
and hematopoietic lineages in fish, and overexpression increases numbers of gata1
positive erythrocytes (Gering et al., 1998). There is some debate as to the role of scl in
12

hemangioblast specification; overexpression of scl expands the population of common
hemangiogenic progenitors (Gering et al., 1998). However, morpholino mediated
knockdown of scl does not disrupt angioblast specification, but does prevent both
primitive and definitive hematopoiesis, suggesting its role is limited to hematopoietic
specification (Juarez et al., 2005). In mice, scl null embryos die in-utero due to a block in
primitive hematopoiesis, but yolk-sac angiogenesis is largely unaffected (Porcher et al.,
1996; Robb et al., 1995; Shivdasani et al., 1995).
Lim domain only 2 (lmo2), a binding partner of scl, is also required for both
primitive and definitive hematopoiesis (Yamada et al., 1998). Null mice die early due to
lack of RBCs in the yolk sac, but like scl, do not have defects in angiogenic specification
(Yamada et al., 2000). Lmo2 also binds other transcription factors, including gata1 and
gata2, acting as a protein scaffold to create hematopoietic regulatory complexes (Omari
et al.). Both scl and lmo2 are expressed in the VBI in Xenopus, and while each
transcription factor has little effect independently, combined overexpression of scl and
lmo2 together results in expansion of the VBI (Mead et al., 2001). Additionally, without
the interaction of scl and lmo2, the DA and subsequent HSCs fail to form in zebrafish
(Patterson et al., 2007).
1.1.8 FGF
Fibroblast growth factors (fgfs) were first identified as being required for
mesoderm induction (Slack et al., 1987). More recent studies demonstrate that fgfs are
specifically required for dorsal mesoderm, and fgfs function to restrict ventral
mesodermal tissues such as the VBI (Kumano et al., 1999). The inhibition of fgf
signaling converts dorsal mesoderm into ventral mesoderm, but is dependent on bmp
signaling (Lee et al.). Consistent with this observation, fgfs and bmps function
13

antagonistically to regulate expression of genes in the VBI (Walmsley et al., 2008; Xu et
al., 1999). Inhibition of fgf signaling expands the expression of erythroid, but not myeloid
or endothelial progenitors in the pVBI (Wang et al., 2008). This agrees with the idea that
fgf signaling is responsible for limiting ventral mesoderm, since the dorsally derived aVBI
is unaffected by inhibition of FGF (Wang et al., 2008). Specifically, fgf4 is thought to be
the molecule responsible for these observations. Overexpression of fgf4 expands
expression of myod, a somite marker, and reduces expression of the hematopoietic
marker, scl (Isaacs et al., 2007). Conversely, inhibiting fgf signaling results in an
expansion of the VBI at the expense of somitic fates (Isaacs et al., 2007; Kumano et al.,
1999). Interestingly, in Xenopus marginal zone explants, fgf induces expression of tie2,
and endothelial marker, at the expense of the erythroid marker, globin (Iraha et al.,
2002). Although affects of fgfs on endothelial tissues have not been observed in whole
embryos, it is possible that fgf mediates decisions between hematopoietic and
endothelial cell fates (Wang et al., 2008).

1.2 Histone Deacetylases
Regulation of chromatin is a critical mechanism by which the cell controls gene
expression (Marks and Xu, 2009). Covalent modification of histones by some enzymes
changes localized chromatin topography and determines the transcriptional activation or
repression of certain promoters (Kouzarides, 2007). Several types and sites of
modification have been discovered so far, including methylation of arginines,
phosphorylation of serines and threonines, and ribosylation of glutamate (Kouzarides,
2007). Lysine residues are susceptible to methylation, ubiquitination, sumylation and
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acetylation (Merrick and Duraisingh, 2007). Chromatin acetylation occurs on the N
terminal tail of histones, and is mediated by enzymes known as histone
acetyltransferases (HATs) which add an acetyl moiety to the amino group of lysine.
Conversely, the removal of acetyl groups from histones is performed by histone
deacetylases (HDACs) (Kouzarides, 1999).
1.2.1 HDAC family
The first mammalian HDAC was isolated in nuclear proteins of bovine thymus
and Jurkat T-cells (Taunton et al., 1996). Now known as hdac1, this newly identified
enzyme showed strong homology to rpd3, a yeast protein of previously unknown
function (Taunton et al., 1996; Vidal and Gaber, 1991). rpd3 was first discovered in yeast
suppressor screens and hypothesized to function as a global transcriptional repressor
(Vidal et al., 1990; Vidal and Gaber, 1991). To date, 18 human HDACs have been
discovered, four of which share structural homology with rpd3 (Gregoretti et al., 2004)
(Figure 1.4). Grouped by their similar catalytic domains, the rpd3 related family of class I
HDACs consists of HDACs 1, 2, 3 and 8. Class I HDACs are expressed in all tissue
types, and tend to localize in the nucleus (de Ruijter et al., 2003; Yang et al., 1997) .
Hdac3 is an exception, as it is found in both the nucleus and cytoplasm (Wanczyk et al.,
2011). Class II HDACs, which share homology with yeast hda1, are subdivided into two
categories. HDACs 4, 5, 7 and 9, class IIa, each contain a single class II catalytic unit.
Class IIb HDACS, 6 and 10, contain two catalytic domains. Class II HDACs are able to
shuttle between the cytoplasm and nucleus, and have more limited tissue distribution
than class I HDACs (de Ruijter et al., 2003). HDAC 11 is the sole member of the class IV
family, and shares structural features of both class I and II HDACs (Gao et al., 2002). All
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Figure 1.4 Histone Deacetylase family. From (Bolden et al., 2006).
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11 enzymes are considered “classical HDACs” in that they require divalent zinc ions for
enzymatic activity. Class III HDACs are known as sirtuins for their homology to yeast sir2
protein. These HDAC’s are NAD dependent, and function predominantly in response to
cellular stress and aging (Donmez and Guarente, 2010; Herranz and Serrano, 2010).
1.2.2 Non-histone protein acetylation
Despite the name, HDACs also modify non-histone proteins. Numerous
transcriptional and metabolic proteins are regulated by acetylation, and many, if not all,
HDACs function outside the territory of chromatin modifications (Spange et al., 2009).
Non-histone protein acetylation can regulate several aspects of protein function including
DNA binding, transcriptional activity, and protein stability (Spange et al., 2009). For
example, the tumor suppressor p53 is acetylated at nine sites that are required for DNA
binding and transcriptional activation of downstream targets (Dai and Gu, 2010).
Interestingly, the c-terminal lysine residues that are acetylated in p53 are also
ubiquitinated (Kruse and Gu, 2008). The prevailing hypothesis is that the two
modifications are exclusive, such that increased acetylation of p53 would prevent
ubiquitination and subsequent degradation, stabilizing the protein (Dai and Gu, 2010). In
support of this, stability of p53 protein increases when HDAC activity is inhibited (Ito et
al., 2001).
Other well studied examples of non-histone protein modification regulating gene
activity are the gata proteins. There are 6 members of the GATA binding transcription
factor family and currently 4 of these members have been shown to be regulated by
acetylation (Patient and McGhee, 2002). Gatas 1, 2, and 3, which are predominantly
required for hematopoiesis, and gata4, which is required for cardiac development, all
show increased DNA binding and activity when acetylated by the HAT, p300 (Boyes et
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al., 1998; Hayakawa et al., 2005; Lamonica et al., 2006; Patient and McGhee, 2002;
Yamagata et al., 2000; Yanazume et al., 2003). Mutation of the acetylation sites in gata1
or gata2 abolishes this affect, indicating that the increased acetylation enhances activity
as a transcriptional activator (Boyes et al., 1998; Hayakawa et al., 2005). In Xenopus,
acetylated gata2 is required for hematopoietic specification, and introducing a nonacetylatable mutant reduces the number of primitive RBCs by 50 percent, indicating the
importance of acetylation for optimal gata2 function (Dalgin et al., 2007). Acetylation
enhances gata4-mediated cardiac differentiation in EBs (Kawamura et al., 2005).
Acetylation of gata3 is also required for its transcriptional activity. Mutation of a critical
lysine in gata3 prevents acetylation at neighboring sites, resulting in a hypoacetylated
protein that acts as a dominant negative (Smith et al., 1995; Yamagata et al., 2000).
Acetylation of gata1 also affects its stability. After the initial activation of gata1 activity,
acetylation subsequently promotes ubiquitination and protein degradation. Acetylation
mutants of gata1 show increased stability in vitro, and have reduced ubiquitin binding
compared to wild type gata1. Additionally, increasing gata1 acetylation by inhibiting
HDAC activity increases ubiquitination and compromises gata1 stability (HernandezHernandez et al., 2006).
Other hematopoietic transcription factors whose activities are regulated by
acetylation include runx1 and scl. These proteins are acetylated by p300 and increased
acetylation correlates with increased DNA binding and transactivation potential (Huang
et al., 1999; Yamaguchi et al., 2004). In the case of scl, increased acetylation also
corresponds to differentiation, since non-acetylable mutants are incapable of promoting
erythroid maturation (Huang et al., 1999).
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1.2.3 Class I HDAC isoform
HDACs function in more than just global histone modification, and acetylation is
carefully regulated to exert specific regulatory roles. Investigations of individual HDACs
reveal they can have specified functions to control these precise outcomes (Haberland
et al., 2009b). Several knockdown and knock out studies in mice and zebrafish have
helped elucidate individual functions of specific HDAC enzymes. While most HDAC null
mice are embryonic lethal at relatively early developmental stages, several targeted
deletions have provided some answers for tissue specific functions for class I HDACs
(Haberland et al., 2009b).
Of the class I HDACs, hdac1 and hdac2 are the most similar, and share 82%
protein homology (Brunmeir et al., 2009). Not surprisingly, several studies demonstrate
redundant functions for hdac1 and hdac2 in mammals. In mice, the heart, brain and lung
develop normally as long as one copy of hdac1 or hdac2 remains intact (Montgomery et
al., 2007). Additionally, conditional deletion of hdac1 in the neural crest, skeletal muscle,
central nervous system, smooth muscle and endothelium does not affect normal
development, presumably due to compensation by hdac2 (Montgomery et al., 2007).
Other examples of hdac1 and hdac2 redundancy include adipogenesis and neuronal
differentiation (Haberland et al., 2010). Hdac1 and 2 are also important for adult
hematopoiesis. Conditional deletion of both enzymes (but not just one) reduces the cell
numbers of erythrocytes and thrombocytes in peripheral blood, and reduces total cell
counts in the bone marrow (Wilting et al.). Lastly, deletion of both hdac1 and hdac2 is
required induce apoptosis in tumor cells (Haberland et al., 2009a). Correspondingly,
siRNA mediated knockdown of hdac1 in transformed cell lines results in an increase of
hdac2 protein levels, and vice versa, suggesting a compensatory mechanism to explain
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the redundancy of the two enzymes (Senese et al., 2007). The different survival
phenotypes of the two knockout mice (hdac1 null mice are embryonic lethal, whereas
hdac2 knockouts survive until after birth) indicate that not all of their functions overlap,
and there are distinctions between the two hdacs (Montgomery et al., 2007). Zebrafish
only possess one hdac1/2 like gene (hdac12 dev); hdac1 mutants and morphants have
global embryonic defects including disruption of neurogenesis and abnormal
development of the heart, pectoral fin, retina, and craniofacial structures (Cunliffe, 2004;
Pillai et al., 2004; Yamaguchi et al., 2005).
Like other class I HDACs, hdac3 null mice are embryonic lethal, dying early in
development due to defects in gastrulation (Bhaskara et al., 2008; Montgomery et al.,
2008). However, conditional deletions in heart and liver demonstrate that loss of hdac3
results in cardiac and hepatocyte hypertrophy, respectively (Knutson et al., 2008;
Montgomery et al., 2008). In both studies, loss of hdac3 interfered with lipid metabolism
by activating peroxisome proliferator-activated receptors (PPAR), resulting in increased
levels of triglycerides, lipids and cholesterol (Knutson et al., 2008; Montgomery et al.,
2008). Surprisingly, neither the heart nor liver showed changes in apoptosis with loss of
hdac3 (Knutson et al., 2008; Montgomery et al., 2008). This is in contrast to
observations made in-vitro. Studies of hdac3 function performed in transformed cell lines
revealed that loss of hdac3 causes delays in cell cycle progression and increased
apoptosis due to increased expression of the cell cycle regulator p21 (Takami and
Nakayama, 2000; Wilson et al., 2006). This is also observed in MEFs, where hdac3 null
cells have a delay in cell cycle progression and increase apoptosis due to defective DNA
double strand break repair (Bhaskara et al., 2008). In zebrafish, hdac3 knockdown by
anti-sense morpholino disrupts cardiac looping and liver development partly due to
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decreased proliferation, though changes in apoptosis were not studied (Farooq et al.,
2008). The diverse nature of these loss-of-function phenotypes emphasizes the
relevance of cellular context in directing normal hdac3 function.

1.3 HDAC Inhibitors
Prior to the discovery of HDAC enzymes, observations in calf thymus
demonstrated the presence of acetylated lysine and arginine residues in the histone
extracts (Phillips, 1963). In a search to find methods of regulating the acetylation state of
histones, microbial compounds trichostatin A (TSA) and trapoxin (TXN) were discovered
to promote global histone acetylation (Kijima et al., 1993; Yoshida et al., 1990). For
several years, employing these HDAC inhibitory compounds (HDACI) was the only
available method to study the effects of acetylation in the cell, until the discovery of
human hdac1 in 1996 (Taunton et al., 1996). Investigations into the effects of exposure
to TSA and TXN revealed they could prevent cell growth, promote differentiation, force
detransformation and initiate cell cycle arrest, laying the foundation for modern HDACI
cancer therapies (Yoshida et al., 1995).
1.3.1 Valproic Acid
Valproic acid (VPA) was first synthesized over 100 years ago from valeric acid,
isolated from the flowering plant Valeriana officinalis (Burton, 1882). For decades after
its discovery, VPA was considered biologically inert, and employed as a solvent. It was
not until 1963 when VPA was used as a vehicle in the study of putative anticonvulsant
molecules that its ability to suppress seizures was observed (Meunier et al., 1963). By
the 1980’s, VPA was approved by the FDA and in the years since has become the most
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widely prescribed antiepileptic drug in the world (Perucca, 2002). Despite its established
efficacy, the molecular mechanisms by which VPA functions as an anticonvulsant and
mood stabilizer are unknown. VPA is a potent teratogen, however, and the severe risk of
birth defects has limited its use as a treatment for women during pregnancy. Exposure
during early development is linked to defective neural tube closure (DiLiberti et al., 1984)
and skeletal defects (Binkerd et al., 1988). Recently, neonatal exposure to VPA has also
been used as a rodent model of autism (Kim et al., 2011; Tashiro et al., 2011).
Investigations into the mechanisms underlying the therapeutic and teratogenic
effects of VPA led to its identification as an HDACI. Two independent groups identified
VPA as an HDACI, because of unexpected observations with VPA exposure. In one
case, VPA induced peroxisomal proliferation in rodent livers without direct activation of
peroxisome proliferator-activated receptor delta (PPAR delta) (Gottlicher et al., 2001). In
another, VPA activated a Wnt responsive Lef-Luciferase reporter construct without
activating the Wnt pathway (Phiel et al., 2001). This led the investigators to find alternate
explanations of their results. Both groups discovered instead that VPA treatment
resulted in hyperacetylation of histones, and direct inhibition of HDAC activity.
Further investigations into VPA demonstrated that its function as an HDACI was
the underlying cause for its teratogenic effects. Zebrafish and Xenopus embryos
exposed to VPA showed the same developmental phenotypes as embryos exposed to
TSA, a structurally unrelated HDAC inhibitor (Gurvich et al., 2005; Phiel et al., 2001). In
contrast, structurally related analogs of VPA that lacked HDAC inhibiting activity did not
cause developmental defects and analogs with intermediate potency caused partial
developmental defects. This pharmacological profile thus demonstrated a close
correlation between teratogenic activity and HDAC inhibition (Gurvich et al., 2005).
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1.3.2 HDACI in Cancer
Aberrant HDAC activity has been linked to a number of different cancers.
Precisely how HDACs are involved varies widely with the type of cancer; however most
cancers are associated with increased HDAC expression (Patra et al., 2001; Zhu et al.,
2004). Interestingly, mutations of HDACs rarely occur, but instead are found in other
components of HDAC repressor complexes (Glozak and Seto, 2007; Marks and Xu,
2009). This has motivated the study of HDACI as potential anti-cancer agents (Minucci
and Pelicci, 2006). A number of HDACI have entered into clinical trials for cancer
treatment, and suberoylanilide hydroxamic acid (SAHA) has already received approval
from the FDA for the treatment of cutaneous T-cell lymphomas (Colussi et al., 2010)
(Frew et al., 2009). Generally, exposure to HDACI causes cell death, differentiation,
decreased cellular proliferation, or a combination of these (Glozak and Seto, 2007;
Richon et al., 2004; Sambucetti et al., 1999). HDACI are capable of inducing receptor
mediated and mitochondrial apoptosis, regulating p53 activity, mediating double strand
break repair, and/or activating reactive oxygen species (Wanczyk et al., 2011). HDACI
induce cell cycle arrest and differentiation through the upregulation of p21 (Wanczyk et
al., 2011). Additionally, HDACI can alleviate tumor invasion by interfering with
angiogenesis (Wanczyk et al., 2011). One important aspect of HDACI that is poorly
understood, and yet adds greatly to their appeal, is that normal cells are more resistant
to HDACI than cancer cells (Johnstone, 2002).

1.3.3 Non-Cancer Therapies
Numerous other biomedical applications of HDACI have been realized in recent
years, independent of their significance in cancer therapies. While the mechanisms are
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unknown, HDACI have shown promising results in the treatment of Huntington’s disease
in both in vitro and animal studies (Sadri-Vakili and Cha, 2006). HDACI have
neuroprotective properties, and have shown promise in animal studies for prevention
and treatment of neurological damage caused by ischemic stroke (Langley et al., 2005).
HDACI have also been used in the generation of iPS cells. By improving activation of
reprogramming factors, HDACI importantly bypass the requirement for c-myc in the
generation of iPS cells (Huangfu et al., 2008). These varied applications of HDAC
inhibitors demonstrate their potential therapeutic value and highlight the importance of
regulation of acetylation during development, homeostasis, disease, and treatment.

24

2. CHAPTER II: VALPROIC ACID INHIBITS PRIMITIVE ERYTHROPOIESIS
2.1 INTRODUCTION
Although histone deacetylases (HDACs) have proven to be critically important
during embryogenesis of many tissues, their role during primitive hematopoiesis remains
unknown. The HDAC inhibitor valproic acid (VPA), long used in the treatment of epilepsy
and bipolar disorder, presents a useful tool for the study of HDAC function, and was
used in the present work to study the role of HDACs during blood development in
Xenopus laevis. Primitive hematopoiesis, which is distinct from adult hematopoiesis,
begins in the ventral blood islands (VBI), a region within the ventral mesoderm where
hematopoietic precursor cells are specified. While the molecules responsible for their
specification are not entirely known, bmp4 has been identified as a key signal for
induction of erythroid precursors in the VBI. Two downstream targets of bmp4, gata1
and gata2 are required for erythroid development and represent early markers of
hematopoiesis (Kelley et al., 1994). Other transcription factors, scl, and runx1, are also
necessary for primitive hematopoiesis (Mead et al., 1998; Tracey et al., 1998). In fact,
while all of these have been identified as important, if not essential, for primitive
hematopoiesis, we currently know little of their exact functions and how they interact with
one another in Xenopus. In this chapter we observed a disruption in the specification of
erythroid progenitors when gastrulating embryos were subjected to VPA. Experiments
were conducted in Xenopus embryos and in naïve ectodermal explants to identify the
genes altered by HDAC inhibition during specification of erythroid progenitors. Finally,
new results are presented that relate our findings in Xenopus with mammalian systems.
Through the present work, we aim to identify a distinct role for HDACs in erythropoiesis.
25

2.2 RESULTS
2.2.1 Exposure to VPA during gastrulation prevents red blood cell development.
Prior studies using VPA and VPA analogs have suggested that the multiple
developmental defects caused by VPA arise through inhibition of HDACs (Gurvich et al.,
2005; Phiel et al., 2001). Embryos exposed to VPA in these experiments displayed
pericardial edema, heart looping defects, curved anterior-posterior axis, and reduced
anterior structures (Figure 2.1 A, B). However, these development defects were
pleiotropic, most likely because embryos were exposed to VPA through multiple
developmental stages. Such broad exposure windows make it difficult to identify specific
roles for HDAC activity. In order to carefully study the effects of VPA treatment on early
Xenopus development, exposure of VPA on embryos was limited to an exposure window
of 4.25 hrs during which gastrulation occurs (Nieuwkoop and Faber stage 10 to stage
12, Figure 2.2). This exposure was chosen because the germ layers are established
during this time, and mesodermal tissues, specifically primitive blood, are specified
(Kumano et al., 1999). Therefore this represents a natural window of exposure to identify
the potential role of HDACs in early blood development.
Stage 10 Xenopus embryos were exposed to 2mM VPA through the end of
gastrulation, then returned to normal growth medium and observed for developmental
defects. At swimming tadpole stages (stage 42), 72 hours after exposure to VPA, visual
inspection revealed that embryos treated with this pulse treatment of VPA lacked
circulating erythrocytes (Figure 2.3 A,B). Additionally, VPA-treatment resulted in
aberrant cardiac looping, and altered cranial cartilage morphology, as confirmed by
alcian blue staining (Figure 2.3 A-D).
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Figure 2.1 Continuous exposure to VPA causes multiple embryonic defects.
Compared to control embryos (A) , exposure to 2mM VPA from stage 19 to stage 28
resulted in pericardial edema, cardiac looping defects, shortened anterior-posterior
anterior
axes
and reduced anterior structures (B, variation shown in C).
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Figure 2.2 Schematic of VPA treatment during Xenopus development.
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Figure 2.3 Pulse exposure to VPA during gastrulation. Compared to control (A), VPA
treatment resulted in absence of blood and cardiac looping defects (B). Arrow indicates
heart containing red blood. Alcian blue staining of cranial cartilage demonstrates
diminished craniofacial growth with VPA (D) compared to control embryos (C).
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However, this relatively short window of VPA treatment did not disrupt normal
establishment of the embryonic anterior-posterior and dorsal-ventral axes (Figure 2.3
B). The rather striking blood phenotype suggests that the exposure to VPA during
gastrulation represents tractable system to study the role of HDACs in primitive
hematopoiesis.
The absence of red blood cells (RBCs) from tadpoles following VPA treatment
was confirmed by staining embryos with benzidine, which marks hemoglobin in blue
(Figure 2.4 A, B). The absence of RBCs in VPA-treated embryos was sensitive to
developmental stage; embryos subjected to VPA treatment an hour later at mid-gastrula
(stage 10.5) retained circulating RBCs at the swimming tadpole stage (Figure 2.4 E- J).
Similarly, initiating exposure prior to gastrulation (stage 4.5 to stage 9) had no effect on
the presence of RBCs at swimming tadpole stage (Figure 2.4 C,D). To confirm that VPA
treatment resulted in a loss of erythrocytes, and not simply a loss of circulation, wholemount in-situ hybridization (WISH) was performed to examine the expression of alpha
T1 hemoglobin (globin), a marker for committed RBCs, in VPA treated embryos. At late
tailbud stages (stage 30), globin is normally expressed throughout the VBI in a
characteristic V-shaped pattern in the ventral mesoderm (Figure 2.5 A). However,
embryos exposed to VPA during gastrulation exhibited a pronounced reduction in globin
expression in the VBI (Figure 2.5 B). These findings were confirmed by qRT-PCR,
which revealed a five-fold reduction in globin expression (Figure 2.5 C). Therefore, the
absence of circulating RBCs in VPA-treated embryos is not a consequence of circulatory
defects (e.g. cardiac looping abnormalities), but instead is due to a reduction in cells
fated to become RBCs.
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Figure 2.4 VPA treatment during gastrulation prevents RBC development.
Circulating RBCs were visualized in tadpoles (stage 43) by benzidine staining (blue) for
hemoglobin (A). RBCs are also present in pronephros (arrow) and in heart (A’, ventral
view). Treatment of gastrulating embryos (stage 10
10-12)
12) with VPA (B) prevented blood
formation, indicated
dicated by benzidine staining (B’, ventral view). Compared to control (C),
exposure to VPA prior to gastrulation did not alter RBC development, as demonstrated
by benzidine staining (D); exposure time as indicated, stage 4.5
4.5-9. Compared to
benzidine staining
ng in controls (E), treatment with VPA for progressively smaller exposure
times (F-J)
J) resulted in a return of red blood cells for treatments initiated from stage 10.5
(H) onward. Initiation of exposure is denoted in the figure; all treatments were carried out
until stage 12.
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Figure 2.5 VPA exposure reduces globin expression in the VBI.
Expression of globin was detected in the VBI by WISH in tailbud embryos (A, stage 31).
In VPA treated embryos (B), globin expression is dramatically reduced, with residual
res
staining restricted to the aVBI. qRT
qRT-PCR (C) confirmed suppression of globin expression
with VPA treatment in stage 28 whole embryos. Numbers indicate embryos with
observed phenotype/total
/total numbers of embryos examined.
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2.2.2 VPA prevents specification of primitive erythrocytes.
To determine whether loss of globin was due to aberrant differentiation or
improper specification of blood, we next examined the expression of runx1, an early
marker for primitive erythroid progenitors at tailbud stages (Tracey et al., 1998;
Walmsley et al., 2008). Runx1 is normally expressed in the VBI, and precedes globin
expression in this domain (Figure 2.6 A). VPA treatment reduced runx1 expression at
early tailbud stages (stage 25) in a pattern similar to what was observed with globin
expression following VPA treatment (Figure 2.6 B). These findings suggest that the
absence of RBCs following VPA treatment is not due to loss of differentiated RBCs, or a
failure to maintain the population, but instead that it is the result of a failure to specify
erythroid precursors.
During late neurula stages, embryos express runx1 in a ventral-anterior
population of cells that co-express markers for erythroid, endothelial, and myeloid
lineages (Walmsley et al., 2002). Called the presumptive aVBI, these cells derive from
the dorsal side of the embryo and will eventually populate the aVBI (3). VPA treatment
reduced runx1 expression in this mixed progenitor population, but not to the same extent
as in the pVBI of older embryos (Figure 2.6 C, D). It is unclear what distinguishes VPAsensitive cells from those that continue to express runx1, however because runx1 is also
important for endothelial and myeloid differentiation, it is probable that runx1 expression
was only inhibited in cells fated to become RBCs. This is supported by the observation
that VPA treatment did not affect runx1 expression in non-hematopoietic tissues such as
neuronal Rohan-Beard cells and the olfactory placode (Figure 2.6 A, B and E, F),
suggesting a distinct role for HDACs in primitive hematopoiesis.
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Figure 2.6 VPA treatment prevents specification of erythroid progenitors.
Primitive erythroid marker runx1 was expressed normally within the VBI in early tailbud
(stage 26) embryos (A). VPA reduced runx1 expression (B). In late neurulae (stage 19),
runx1 is expressed in precursors of the aVBI (C). VPA treatment reduced runx1
expression in neurula stage embryos (D). Examinin
Examining
g the dorsal side of control (E) and
VPA treated (F) embryos, expression of runx1 was observed in Rohan
Rohan-Beard
Beard cells in the
same embryos as C) and D) (anterior view), and was not affected by VPA. Similarly,
expression of runx1 in the olfactory placodes (arr
(arrows,
ows, A and B) was unaltered with VPA.
Numbers indicate embryos with observed phenotype/total numbers of embryos
examined.
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Because runx1 was only partially diminished in neurula stage embryos, and cells
expressing runx1 at this time co-express other VBI derived markers, we speculated that
VPA only affects a subset of these cells: specifically those fated to become erythrocytes.
This would permit the remaining runx1 positive cells to differentiate into other VBI
derived tissues without interference from VPA, as was observed. To test this, we
examined expression of endothelial marker aplnr and myeloid marker mpo. Expression
of each was unchanged with VPA treatment, suggesting that VPA treatment interferes
only with specification of the erythroid lineage, and not other lineages arising from the
aVBI (Figure 2.7 A-D). Loss of RBCs was further confirmed by in-situ for scl, a marker
for primitive erythrocytes, which is reduced in the VBI of tailbud (stage 30) embryos
treated with VPA (Figure 2.7 E, F). Expression of the erythroid marker, gata1, is also
diminished with VPA treatment in the VBI of tailbud (stage 30) embryos in a similar
pattern to globin (Figure 2.7 G, H). These results demonstrate that VPA specifically
inhibits generation of primitive erythrocytes in the developing embryo.
It is possible that exposure to VPA results in increased apoptosis of the cells
specified to become RBCs or that the erythroid progenitors could have aberrant
proliferation which results fewer primitive blood cells. To determine whether VPA
disrupts primitive erythropoiesis by either increasing apoptosis or reducing proliferation
of hematopoietic progenitor cells, TUNEL and phospho-H3 staining were performed,
respectively. No cell death was observed within the VBI of either VPA-treated or control
embryos (Figure 2.8 A-E). Additionally, no differences in proliferation were observed at
either the late gastrula stage (stage 12), or in the VBI of neurula (stage 15) and tailbud
(stage 30) stages (Figure 2.8 F-I).
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Figure 2.7 VPA inhibits expression of erythroid but not endothelial and myeloid
markers. (A) expression of a myeloid marker, mpo, was unaltered by VPA treatment (B).
(B)
aplnr expression in the developing vasculature of stage 29/30 embryos (C)
( was
unaffected with VPA treatment (D); lateral view, anterior to the right (A
(A-D).
D). Expression of
two additional erythroid markers, scl (E, F) and gata1 (G, H) were expressed ventrally in
controls (E, G) and expression was greatly reduced with VPA treatme
treatment
nt (F, H); ventral
views (E-H). Numbers indicate embryos with observed phenotype/total numbers of
embryos examined.
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Figure 2.8 Treatment with VPA does not alter cell proliferation or cell death.
TUNEL staining on stage 11 embryos reveals no apoptosis in control (A) embryos or in
embryos treated with VPA (B). Cyclohexamide (CHX) treated embryos serve as a
positive control (C). The ventral side of stage 20 embryos (D-F) revealed no differences
in apoptosis between control (D) and VPA-treated (E) embryos. Again, CHX was used
as a positive control (F). No apoptosis was seen in stage 25 control (G) or VPA-treated
(H) embryos. Phospho-H3 antibody staining demonstrates no change in cell proliferation
from control (I) to VPA-treated embryos (J). Ventral views of tadpoles also demonstrated
no differences in proliferation between control (K) and VPA-treated (L) embryos.
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Figure 2.8 Treatment with VPA does not alter cell proliferation or cell death.
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Another possible explanation for our observations is that VPA may re-specify
cells normally fated to become blood into other embryonic tissues. To test if this is the
case, expression of multiple mesodermal, ectodermal and neural crest derived markers
were examined, including xbra (pan-mesoderm), vent2 (ventral mesoderm), myod1
(dorsal mesoderm), hoxb9 (posterior neural), xpo (ventral- posterior), nkx2.5 and tbx20
(cardiac mesoderm), xlim1 (lateral mesoderm), otx2, xrx, and krox20 (anterior neuroectoderm), and slug (neural crest) (Figure 2.9 A-X).
VPA treatment did not alter expression patterns for any of the markers examined,
consistent with the apparently normal tadpole morphology at later stages. This indicates
that exposure to VPA during the gastrula stage does not alter global patterning or cell
survival and proliferation, but directly affects specification of primitive hematopoietic
progenitors.
2.2.3 VPA-mediated inhibition of hematopoiesis occurs downstream of bmp4.
Primitive hematopoiesis in vertebrates requires bmp signaling, particularly the
ligand bmp4 (Hemmati-Brivanlou and Thomsen, 1995; Sadlon et al., 2004; Snyder et al.,
2004). Therefore, we next investigated whether VPA inhibits primitive hematopoiesis by
directly altering bmp signaling. VPA could either reduce bmp4 expression or enhance
expression of bmp antagonists, including noggin (nog) and chordin (chd), which are
expressed in the gastrula and play critical roles in regulating dorsal-ventral patterning
(Kumano et al., 1999). We therefore used WISH to examine expression of bmp4, nog,
and chd in gastrula stage embryos. VPA treatment did not significantly alter expression
of these genes, indicating that loss of RBCs occurs despite normal expression of bmp4
and its inhibitors (Figure 2.10 A-F).
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Figure 2.9 Marker analysis with VPA treatment. Untreated embryos (control) are to
the left and VPA treated embryos are to the right, unless otherwise indicated. myod (A,
B), vent2 (C, D), xbra (K, L) are shown in posterior view, xpo (E, F), xlim (M, N) , krox20
(O, P) are shown in lateral view, anterior to the left, nkx2.5 (G, H), xrx1 (I, J), slug (Q, R),
otx2 (U, V) are shown in the anterior view, and hoxb9 (W, X) are shown in the dorsal
view, anterior to the left. myod, vent2, xpo, xbra- late gastrula. nkx2.5, xrx1, slug, hoxb9neurula stages. xlim1, krox20, tbx20, otx2- tailbud stages.
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er analysis with VPA treatment.
Figure 2.9 Marker
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Because the expression of bmp4 was unaffected with VPA treatment, we next
examined whether VPA regulates blood development downstream of bmp signaling. To
do so, we made use of naïve ectodermal explants, a tool often used to study
hematopoietic specification in Xenopus (Hemmati-Brivanlou and Thomsen, 1995; Xu et
al., 1999). We examined globin induction in ectodermal explants in response to bmp4.
As reported previously, bmp4 induces blood development in ectodermal explants, as
assessed by induction of globin (Hemmati-Brivanlou and Thomsen, 1995) (Figure 2.10
G). However, when explants overexpressing bmp4 were exposed to VPA, globin
expression was markedly reduced (Figure 2.10 G). This suggests that HDAC activity is
required downstream of bmp4 to specify blood formation. Bmp4 overexpression in
ectodermal explants also induced runx1 expression; this too was blocked by VPA
treatment (Figure 2.10 H).
Bmp4 signaling is mediated through phosphorylation of its downstream effectors,
smads. To determine whether VPA-mediated loss of runx1 and globin expression results
from direct interference with bmp signaling, the effects of VPA on smad phosphorylation
was examined. Immunoblotting for phosphorylation of smad1/5/8 (P-smad) in whole
embryos and bmp4 expressing explants revealed a small change in P-smad levels after
VPA treatment (Figure 2.11 A, B). However, this difference was too minor to account for
the significant effect VPA has on blood development. These findings suggest that global
inhibition of the bmp4 signaling pathway cannot account for VPA mediated
hematopoietic defects. This was further confirmed by examining the effects of VPA on
the expression of downstream targets of bmp4 that are not involved in hematopoiesis;
BMP-induced mesodermal marker, xbra, was not affected by VPA treatment (Figure 2.9
K, L). However, expression of gata1 and gata2 was reduced with VPA treatment at the
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Figure 2.10 VPA prevents hematopoietic specification in ectodermal explants
downstream of bmp4. Expression of bmp4 (A, B), chordin (C,D), and noggin (E,F) in
late gastrula stage embryos is unaffected by VPA (B, D, F); orientation: posterior view,
dorsal to the top. qRT-PCR
PCR of ectodermal explants harvested at tailbud stages (G, H,
stage 28-31). Injection
tion of bmp4 mRNA (2 ng) induced globin expression and VPA
inhibited this effect (G). Injection of bmp4 induced expression of runx1 and VPA blocked
this effect (H). Numbers indicate embryos with observed phenotype/total numbers of
embryos examined.
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Figure
re 2.11 VPA inhibits BMP signaling downstream of smad activity.
activity Immunoblots
of whole embryo protein levels show no change in smad phosphorylation with VPA
treatment for either 2.5 or 4.25 hour exposures (A). In ectodermal explants, P-smad
P
levels were unaffected
fected in bmp4 expressing explants when VPA was present (B). qRTqRT
PCR reveals a reduction in gata1 (C) and gata2 (D) expression levels in stage 12
embryos following VPA treatment. By stage 20, expression levels of both have returned
to normal.
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end of gastrulation (stage 12), 4 hours after exposure to VPA was initiated (Figure 2.11
C, D). Interestingly, the reduced expression of gata1 and gata2 recovered to normal
levels at neurula stages (Figure 2.11 C, D). These observations suggest that VPA does
not inhibit all bmp mediated signaling, but rather a subset that is critically important for
blood specification.
2.2.4 VPA inhibits gata-mediated hematopoietic specification in explants.
The transcription factors gata1 and gata2 are both regulated by bmps in Xenopus
and zebrafish (Huber et al., 1998; Lieschke et al., 2002; Zhang and Evans, 1996), and
are required for hematopoiesis in many vertebrates. Overexpression of either gata1 or
gata2 can induce globin expression in Xenopus ectodermal explants (Xu et al., 1997)
(Figure 2.12 A, B). To determine whether HDAC activity is required downstream of gata
signaling for blood specification, gata1 or gata2 mRNA was injected into ectodermal
explants and globin expression was assessed by qRT-PCR. VPA treatment blocked
globin expression in explants expressing gata1, and reversed globin expression in gata2
expressing explants (Figure 2.12 A, B). These results suggest that in explants, HDAC
mediated effects function downstream of gata activity.
Endogenous bmp signaling maintains epidermal fates and suppresses neural
induction in ectodermal cells in Xenopus, whereas inhibition of endogenous bmp
signaling induces neural markers in ectodermal explants. Furthermore, overexpression
of either bmp4 or gata1 can block induction of the neural marker ncam (Shibata et al.,
1998; Xu et al., 1997). Consistent with its ability to inhibit bmp4 and gata1 -induced
hematopoiesis, VPA induced expression of endogenous ncam in ectodermal explants,
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Figure 2.12 VPA blocks induction of globin by gata1 and gata2. qRT-PCR
qRT
of
ectodermal explants injected with gata1 (A) or gata2 (B) mRNA shows upregulation of
globin expression, and suppression of this effect in the presence of VPA.
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Figure 2.13 VPA does not neuralize ectodermal explants In uninjected ectodermal
explants. VPA induces ncam (A) expression, but not other neural markers such as
n-tubulin (B) or sox2 (C).
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indicating that HDAC inhibition disrupts endogenous gata1 and bmp4 activity (Figure
2.13 A). However, VPA did not neuralize explants, as indicated by failure to induce
other neural markers such as sox2 and n-tubulin (Figure 2.13 B, C). Together, these
results suggest that HDAC activity is required for bmp4 signaling downstream of gata1.
2.2.5 VPA upregulates FGF signaling.
Antagonizing both bmp4 and gata1 during hematopoiesis are fgfs, which
negatively regulate primitive hematopoiesis in Xenopus (Xu et al., 1999). Induction of
ncam expression in ectodermal explants requires both the presence of fgfs and an
inhibition of bmp signals, while induction of globin requires the inverse: upregulation of
bmps and downregulation of fgfs (Xu et al., 1999). Since VPA treatment can induce
ncam and block bmp4 induced globin expression in ectodermal explants, its effects
could be mediated through activation of fgfs. To test if VPA could be inhibiting blood
specification though an increase in FGF signaling, we attempted to rescue VPA treated
embryos with an fgf receptor inhibitor, PD166866. By inhibiting FGF signaling in
embryos during gastrulation, we partially rescued the effects of VPA on runx1
expression, preventing loss of runx1 expressing cells in the presumptive VBI at neurula
stages (Figure 2.14 A-D). This suggests that, at least in part, HDAC activity is necessary
to suppress FGF signaling during hematopoiesis. Consistent with these findings, we
observe an increase in fgf4 expression with VPA treatment at late gastrula and neurula
stages (stage 12 and 20) by qRT-PCR (Figure 2.14 E). These findings were further
confirmed by examination of a mesodermal target of FGF signaling, wnt8 (Hong et al.,
2008). Wnt8 is normally expressed in the lateral mesoderm, and VPA treatment
upregulated its expression, as observed by WISH (Figure 2.14 F, G). Together these
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Figure 2.14 VPA activates FGF signaling
signaling. Runx1 expression, which compared to
control (A) is repressed with VPA (B), can be restored with the introduction of an fgf
inhibitor (FGFI, C); FGFI alone has no effect on runx1 expression compared to control
(D). In
n whole embryos, qRT
qRT-PCR revealed an upregulation of fgf4 in VPA treated
embryos compared to controls (E). Compared to control (F), wnt8 expression is
expanded anteriorly with VPA treatment (G); lateral view anterior to the left.
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results suggest that exposure to VPA activates FGF signaling and may account for some
VPA-mediated developmental defects.
2.2.6 VPA acts upstream of runx1 to inhibit primitive hematopoiesis.
Because runx1 is required for primitive erythropoiesis in Xenopus (Tracey et al.,
1998), we tested whether runx1 could rescue the effects of VPA treatment on blood
development. Benzidine staining demonstrated that overexpression of runx1 partially
rescues erythropoiesis in VPA-treated tadpoles (Figure 2.15 A-D). This suggests that
HDAC activity is required upstream of runx1 expression to regulate erythroid
specification. When considered in the context of the above findings, these data suggest
that VPA acts downstream of bmp4, between gata1 and runx1, to inhibit erythropoiesis.
2.2.7 VPA inhibits primitive erythropoiesis in mice.
To determine if the effects observed with VPA treatment on primitive
erythropoiesis translate to mammals, we tested the effects of VPA treatment on mouse
embryogenesis. In collaboration with the Palis lab at the University of Rochester, we
tested the ability of VPA to inhibit yolk sac hematopoiesis in mouse embryo explants
cultures. Wild type mice (n=4) were harvested at neural plate stage (E7.5) and cultured
with stem cell factor and erythropoietin, cytokines required for differentiation of primitive
erythrocytes (McGann et al., 1997). Embryos were exposed to 0.8mM (n=4) or 2mM
(n=4) of VPA and cultured for 48 hours, after which individual cells were assayed for cell
viability using trypan blue exclusion and for hemoglobin production by benzidine
staining. The 0.8mM dose of VPA had little effect on the total number of cells per embryo
compared to wild-type. However, 2mM VPA treatment reduced overall cell numbers
(Figure 2.16 A).
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Figure 2.15 Runx1 expression rescues VPA
VPA-mediated
mediated hematopoietic defects.
Benzidine staining of hemoglobin (blue) in untreated stage 43 tadpoles (A). Treatment
with VPA (B) inhibited RBC development. Injection of runx1 partially recovered
erythrocyte development (C) in VPA treated embryos. The percent of embryos that
stained positively for RBC was quantified for each treatment (D).
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The total number of live cells decreased in a dose dependent manner; however both
doses had a similar decline in cell viability (Figure 2.16 B, D). Both doses of VPA
treatment significantly reduced the number of benzidine positive cells (Figure 2.16 C).
There were no benzidine positive cells at E7.5 when the embryos were harvested (data
not shown). Strikingly, only untreated control embryos develop hemoglobin expressing
cells after 48 hours of culture, suggesting that VPA prevents the initiation of RBC
generation during mouse development. These results support our findings in Xenopus
and suggest a strongly inhibitory effect of VPA on erythroid development, despite
possible toxicity with drug treatment in the mouse embryo.
Next, we wanted to assay the effects of VPA on erythroid progenitor cell
development in mouse. Neural plate stage (E7.5) mouse embryos were cultured in the
presence of VPA for 48 hours, after which individual cells were isolated, plated, and
assayed for primitive erythroid colony forming cells (EryP-CFC), indicative of erythroid
progenitors. Wild type embryos were left untreated (n=6) or exposed to two doses of
VPA, 0.4mM (n=5), and 0.8mM (n=6). The number of EryP-CFC decreased in a dosedependent manner with VPA treatment, but did not affect overall cell numbers and
viability (Figure 2.16 D-F and data not shown) These data suggest that at lower, less
toxic doses, VPA blocks development of primitive erythroid progenitors in mouse
embryos.
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Figure 2.16 VPA inhibits yolk-sac erythropoiesis in mice. Mouse embryo explants
were cultured for 48 hours and total cell number determined (A). Less total cells were
observed with VPA treatment, along with a reduction in viable cells, as determined by
trypan exclusion (B). Benzidine staining revealed a dramatic reduction in RBCs for
embryos cultured in the presence of both low and higher doses of VPA (C). Due to a
reduction in total cells and viable cells, the overall percent viability was only slightly
reduced with VPA treatment (D). Differences in the presence of precursors were
identified by isolating cells and examining EryP-CFC of embryos cultured under control
and VPA conditions. VPA induced a dose-dependent reduction in colony forming cells
(E) despite no changes in cell viability (F). N=4 embryos per group. Experiments were
conducted by the Palis Lab.
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Figure 2.16 VPA inhibits yolk-sac
sac erythropoiesis in mice
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2.3 CONCLUSION
In the present chapter, VPA was used to identify an essential role for HDACs in
primitive hematopoiesis. While the precise function of HDACs is as yet unclear, we
observed that VPA does not interfere directly with bmp signaling, but that it does reduce
the expression of several target genes specific to the erythroid program, such as runx1,
gata1, and scl. Interestingly, ectodermal explant studies suggest that of these
transcription factors, runx1 and gata1 also require HDAC activity in order to induce
erythroid differentiation, suggesting that HDACs may play multiple roles at different
levels of this transcriptional cascade. Finally, experiments in mouse embryos
demonstrated that VPA similarly inhibits primitive blood formation in a mammalian
system, suggesting that the findings of this work could have direct implications for the
role of HDACs in hematopoiesis in humans, and also suggests a potential mechanism
for the teratogenic effects of VPA. While we have established a role for HDACs in
hematopoiesis, we have not yet identified a specific HDAC responsible for these
observed effects. In the next chapter, this is addressed through the use of
pharmacological inhibitors and knockdown studies.

2.4 MATERIALS AND METHODS
Embryo manipulations and drug treatment:
Embryos were obtained, cultured, and microinjected as described previously (Sive et al., 2000) in
0.1XMMR (MMR: 100mM NaCl, 2mM KCl, 2mM CaCl2, 1mM MgSO4, 5mM HEPES, pH 7.4) at
RT for approx 18 hrs (stage 32, tadpole). Embryos were staged according to (Nieuwkoop and
Faber, 1994) . Capped mRNAs were produced by in vitro transcription using the mMessage
mMachine Kit (Ambion). See Appendix for individual construct information. All injections were
made marginally (or in the animal region, for explant experiments) in each blastomere of 2-cell

55

stage embryos. Ectodermal explant assays were performed as described previously (Sive et al.,
2000). Explants were excised using a Gastromaster tip at stage 8, cultured until tailbud stages
(stage 28-31), and collected for quantitative RT-PCR.
Valproic acid (Sigma) was used at a final concentration of 2mM and administered at stage 10 and
washed out at stage 12, unless otherwise noted. PD166866 (EMD Chemicals) was administered
from stage 8 at a final concentration of 0.6mM.
In-situ hybridization, benzidine staining and immunoblotting:
Anti-sense probes using Dig-UTP (Roche) were synthesized using the Megascript Kit (Ambion).
Whole-mount in situ hybridization was performed as described previously (Harland, 1991). See
Appendix template cDNA information. Benzidine staining was performed as described on
www.xenbase.org. Color development was allowed to proceed for 3 minutes. Alcian Blue
performed as described in (O'Donnell et al., 2006). PhosphoH3 and TUNEL staining was
performed as described (Wu et al., 2006). Immunoblotting was performed by lysing 10 embryos
or 20 animal caps in 100µl of 1X RIPA (50mM Tris-HCl, pH 7.4, 1% Igepal CA-630 (NP-40),
0.25% Na-Deoxycholate, 150mM NaCl, 1mM EDTA, 0.5mM DTT) with phosphatase and
protease inhibitors (Sigma P8340, P2850, and P5726) centrifuged at 20,000xg for 10 mins at
4ºC, and supernatants were collected for SDS-PAGE and immunoblotting. 0.5 or 1 embryo
equivalent was detected with anti-phosphoSmad1/5/8 or anti-gapdh (Cell Signaling).
RNA quantitation:
Quantitative RT-PCR (qRT-PCR) was performed as described previously (Blythe et al.). For
each experiment, individual samples were analyzed in triplicate. Data were analyzed by first
normalizing to the house-keeping gene ODC as loading control, and then calculating fold change
compared to the indicated control condition using the ∆∆C(t) method (reviewed in (Taneyhill and
Adams, 2008). Embryonic cDNA was synthesized using oligo(dT)15mer primers as described
(Yang et al., 2002). See Appendix for primer information.
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3. CHAPTER III: VALPROIC ACID CAUSES DEVELOPMENTAL DEFECTS
THROUGH HDAC3 INHIBITION
3.1 INTRODUCTION
In Chapter II, we identified a severe blood phenotype in Xenopus embryos
exposed to VPA during gastrulation. The effects of VPA were shown to act downstream
of bmp4, a key agent in the initiation of the hematopoietic program. While the VPAinduced phenotype was interpreted as a result of HDAC inhibition, it remains unclear if
that is indeed the cause for the resulting phenotype, and if inhibition of a specific HDAC
could account for all of the defects observed. In the present chapter, we address these
questions, investigating the precise mechanism by which VPA inhibits blood formation.
We examine the localization and method of cellular entry of VPA using a screening
approach in Dictyostelium. A series of compounds targeted at different overlapping
classes of HDACs are used to phenocopy the effect of VPA in order to identify candidate
isoforms that may be involved in hematopoiesis. Based on these findings, one particular
class I HDAC, hdac3, is investigated for its role in primitive hematopoiesis, using a
knockdown/morpholino approach that reproduces the VPA phenotype. This work
identifies for the first time a precise role for HDACs in Xenopus and specifically
implicates hdac3 in hematopoiesis.

3.2 RESULTS
3.2.1 VPA mediated hematopoietic defects are due to class I HDAC inhibition
VPA is an established HDAC inhibitor, but also has activities that are
independent of HDACs, based on pharmacological analyses with VPA structural analogs
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(Gurvich et al., 2004; Nau et al., 1991). To confirm that the hematopoietic effects
observed with VPA were indeed a result of HDAC inhibition, a structurally unrelated
HDAC inhibitor, trichostatin A (TSA) was investigated for its potential to prevent blood
specification. TSA reduced runx1 expression in the VBI in a similar pattern to VPA, and
inhibited globin expression in bmp4 expressing ectodermal explants (Figure 3.1 A-C, E).
These findings suggest that VPA mediated inhibition of hematopoiesis is indeed through
disruption of HDAC activity. Moreover, valpromide (VPM), an amide derivative of VPA
that does not inhibit class I or class II HDACs (Gurvich et al., 2004), did not affect runx1
expression (Figure 3.1 D). This is in agreement with previous work that demonstrated
global developmental defects caused by long term exposure to VPA can be
recapitulated with TSA, but not VPM (Gurvich et al., 2005). More generally, this implies
that developmental defects associated with VPA are the result of HDAC inhibition.
Previous work suggested that VPA inhibits both class I and class II HDACs, but
those results were confounded by experimental artifacts due to overexpression or
coimmunoprecipitation (Gurvich et al., 2005). Thus, we used recombinant human
HDACs and substrates that distinguish between class I and class II HDACs to determine
the IC50 of VPA on specific HDAC isoforms. We discovered VPA is a selective inhibitor
of class I HDACs, and not a pan-HDAC inhibitor as previously thought (Figure 3.2 and
(Fass et al.)). Butyrate, a related short-chained carboxylic acid HDAC inhibitor, and its
derivative phenylbutyrate, are also inhibitors of class I HDACs (Figure 3.2). Butyrate has
previously been shown to cause similar phenotypes as VPA in both Xenopus and
zebrafish (Gurvich et al., 2005). Interestingly, the hydroxamic acid derivative of VPA,
valpropylhydroxamic acid (VAHA) has little effect on class I HDACs, and instead inhibits
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class II HDACs (Figure
Figure 3.2 and (Fass et al.)). Classification of the HDAC targets of VPA
and other related molecules allows us to then identify targets for VPA in the prevention

Figure 3.1 VPA mediated hematopoietic defects are due to inhibition of HDACs.
Runx1 expression in the anterior ventral region of late neurula stage control embryos (A,
stage 18). TSA suppressed runx1 expression (B). VPA-treated
treated embryos demonstrated
reduced runx1 expression (C). V
VPM did not change runx1 expression (D). Bmp4 mRNA
(2ng) induced globin expression in ectodermal explants and TSA (Bmp+TSA) prevented
this effect (E). Numbers indicate embryos with observed phenotype/total numbers of
embryos examined.
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ry of IC50 values for Carboxylic and Hydroxamic HDAC
Figure 3.2 Summary
inhibitors. Schematic chemical structures are shown for HDAC inhibitors and their
derivatives (top). IC50s for each of the HDAC inhibitors are shown in the table (bottom)
where the compound number corre
corresponds
sponds to the numbering designation above.
Experiments were conducted by the Haggarty Lab.
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of blood development. Our results with VPA suggest that the developmental defects we
observe could be mediated through a class I HDAC. This is further supported by the fact
that treatment with VAHA, an inhibitor of class II HDACs, does not interfere with overall
embryo development or RBC formation (Figure 3.3 A-C). As expected, VAHA did not
alter histone 3 K9/14 acetylation, but did increase acetyl-tubulin levels (Figure 3.3 D, E),
confirming that VAHA effectively inhibited class II HDACs in the embryo.
To test whether inhibition of a specific class I HDAC is responsible for the
developmental phenotype we observe with VPA treatment, we utilized two class I
selective HDAC inhibitors that differ in their activities against hdac3. CI-994 inhibits
hdacs 1, 2, and 3 with similar IC50s whereas Compound-60 (C60) preferentially inhibits
hdac1 and hdac2, and is significantly less potent against hdac3 (Methot et al., 2008).
Inhibition of hdac1 and hdac2 with C60 had no apparent effect on development. On the
other hand, inhibition of hdac3 along with hdacs 1 and 2 with CI-994 exposure closely
mimicked the developmental effects of VPA (Figure 3.4 A-D). Both C-60 and CI-994
inhibited overall HDAC activity in vivo, as assessed by increased global histone
acetylation in the embryo (Figure 3.4 E). This observation suggests that hdac3 may be a
major target responsible for VPA-induced developmental defects.
3.2.2 HDAC3 is essential for primitive hematopoiesis in Xenopus
To further investigate whether class I HDACs, and hdac3 in particular, may be
involved in primitive hematopoiesis, we examined the expression of class I HDACs at
various stages during Xenopus development. Interestingly, we find expression of hdac1
remains stable through late blastula and early neurula stages (stage 9 to stage 14),
however expression of both hdac2 and hdac3 taper off significantly after the onset of
gastrulation (Figure 3.5 A-B).
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Figure 3.3 VAHA, a class II HDAC inhibitor does not cause developmental defects
in Xenopus. Compared to control embryos (A), embryos treated with the class II HDAC
inhibitor VAHA had no noticeable defects (B), while as shown above VPA treatment
resulted in multiple developmental defects (C). Measurement of tubulin acetylation
demonstrated that VAHA effectively inhibited class II HDACs, reflected by a dose
dependent increase in acetylated tubulin, a known substrate of class II HDACs (D).
Conversely VAHA did not affect histone acetylation at either low or high concentrations,
while VPA treatment significantly increased histone acetylation (E).
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Figure 3.4 An inhibitor of HDACs 1, 2, and 3, but not an inhibitor of HDACs 1 and 2
phenocopies VPA treatment
treatment. Compared to control (A), lateral views of stage
stag 45
tadpoles treated during gastrulation with the HDAC1 and HDAC2 inhibitor C-60
C
resulted
in normal embryos (B), while VPA
VPA-induced
induced developmental defects (C) were mimicked by
CI-994,
994, which inhibits HDACs 1, 2, and 3. VPA (class I HDAC inhibitor), CI-994
CI
(specific
inhibitor of HDACs 1, 2, and 3), and C
C-60
60 (specific inhibitor of HDACs 1 and 2) increase
histone acetylation at 2 and 4 hours post treatment, as demonstrated by western
blotting. (D).
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Figure 3.5 Time course of expression levels for class I HDACs in Xenopus.
Xenopus qRTPCR of whole embryos at various developmental stages between 9 and 17.
17
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demonstrated distinct and transient changes in expression for hdac1 (A), hdac2 (B), and
hdac3 (C).
To test the requirement for hdac3 further, we designed a translation blocking
oligonucleotide morpholino against Xenopus hdac3 (HDAC3 MO). Knockdown of hdac3,
but not hdacs1 and hdac2, was confirmed by western blot (Figure 3.6 C). Knockdown of
hdac3 reduced globin expression in a dose dependant manner (Figure 3.6 D), similar to
VPA treatment. Additionally, by using benzidine staining we observed a loss of
circulating RBCs with MO injection that mirrors VPA treatment (Figure 3.6 A, B). WISH
in late neurula (stage 20) embryos showed a strong decrease in runx1 expression in the
presumptive VBI, not unlike embryos exposed to VPA (Figure 3.6 F, G). Injection of
RNA encoding human hdac3 (hHDAC3), which does not contain the MO binding site,
partially rescued globin expression in hdac3 knockdown embryos (Figure 3.6 E). Hdac3
knockdown also closely phenocopied the morphological defects caused by VPA, TSA,
and CI-994 (Figures 3.6 B, 3.1 and 3.4), suggesting that multiple VPA-induced
developmental defects can be attributed to inhibition of hdac3. In explants expressing
bmp4, loss of hdac3 prevented globin induction, further confirming that VPA inhibits
blood development by inhibiting hdac3 (Figure 3.7 A). Also like VPA, injection of HDAC3
MO is able to induce ncam expression in explants (Figure 3.7). Interestingly, loss of
hdac3 does not have a significant effect on bmp4 expression (Figure 3.7 C), suggesting
that hdac3 plays a critical role in primitive erythropoiesis, and probably functions
downstream of bmp4 signaling.
3.2.3 VPA enters the cytoplasm through a bicarbonate channel.
In Xenopus and zebrafish, VPA is administered by dilution into the culture
medium and exerts its effects without the need for carriers or microinjection. The
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Figure 3.6 Knockdown of hdac3 inhibits primitive hematopoiesis. Benzidine
staining of 43 stage tadpole indicated normal RBC development (A). RBCs were
reduced in embryos injected with hdac3MO (B). hdac3MO
MO reduced hdac3 protein levels,
but not hdac1/2 levels, as demonstrated by western blot (C); u.i. = uninjected. Runx1
and globin expression
n demonstrate dose
dose-dependent
dependent reductions in response to
increasing concentrations of hdac3MO (D). qRT-PCR
PCR indicated that compared to
uninjected controls, hdac3
hdac3MO
MO reduced globin expression, and was partially rescued by
co-injection of hdac3MO
MO and human hdac3 RNA (MO+RNA) (E). hdac3MO
MO reduced
runx1 expression in whole embryos at stage 20, ventral view.
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mechanism by which VPA crosses the cell membrane and reaches its cytoplasmic
targets is still unknown. It may enter the cell via diffusion through the lipophillic
membrane or actively enter through a membrane channel. Alternatively, it has been
proposed that VPA acts extracellularly through receptors on the cell surface (Kessel et
al., 2001). It is known that interfering with the catalytic pocket of zinc dependent HDACs,
such as hdac3, is how most HDAC inhibitors function, suggesting a direct role for VPA
within the cell (Marks and Xu, 2009). As such, we wanted to fully understand how VPA
may be entering into the cell to exert its effects as an HDAC inhibitor. To do so, we
exposed Dictyostelium to tritiated VPA (3H-VPA), and observed localization of VPA over
time. VPA enters the cells within 15 seconds, and localizes primarily in the cytoplasmic
compartment (Figure 3.8 A and (Terbach et al.)). To determine how VPA enters the cell,
Dictyostelium were treated with 50 uM carbonyl cyanide ptrifluoromethoxyphenylhydrazone (FCCP) to depolarize the membrane. This prevents
VPA from being transported into the cytoplasm, suggesting that VPA enters the cell by
exploiting proton gradients through an active transporter, and not by passive diffusion
(Figure 3.8 B and (Terbach et al.)).
In Dictyostelium, VPA causes growth and developmental retardation at
concentrations of 1 and 2mm, respectively (Boeckeler et al., 2006) . To identify the
protein responsible for transporting VPA into the cell, we utilized a restriction enzyme
mediated integration screen to isolate mutants that were resistant to the effects of VPA.
In total, 26 mutants were identified, 14 from the growth screen and 12 in the
developmental screen. All 26 mutants were deficient in slc4, a putative bicarbonate
transporter that shares 17 to 30% homology with mammalian SLC4 transporter family
(Terbach et al.). Scl4 orthologs are also found in both zebrafish and Xenopus, both
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sharing approximately 30% protein sequence homology with dicytostellium (Terbach et
al.).
To test if VPA enters Xenopus cells through a bicarbonate channel such as Scl4,
we co-administered VPA and sodium bicarbonate to 16-cell embryos through tailbud
stages (stage 5 to stage 40). As reported previously (Gurvich et al., 2005; Phiel et al.,
2001), long term exposure of Xenopus embryos to 2mM VPA causes shortened anteriorposterior axis, developmental delay, and pericardial edema, and defects in cardiac
looping (Figure 3.8 D). Adding bicarbonate with VPA to embryos provides a dosedependent block to VPA-induced developmental defects, with partial rescue of both
developmental delay and growth defects at 1mM or 3mM bicarbonate (Figure 3.8 E, F)
and virtually complete rescue at higher concentrations (5mM and 10mM ) of bicarbonate
(Figure 3.8 G, H). These results suggest that in Xenopus VPA may be entering the
embryo through a slc4-related bicarbonate channel.

68

Figure 3.7 hdac3 MO phenocopies VPA treatments
treatments. Induction of globin by bmp4 was
inhibited by hdac3 MO in ectodermal explants (A). hdac3 MO upregulated expression of
ncam,, similar to VPA (B). In whole embryos, injection of the hdac3 MO did not affect
bmp4 expression (C).
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Figure 3.8 Cellular uptake of VPA occurs through a bicarbonate channel. Timecourse analysis of H3 labeled VPA reveals rapid uptake into the cytoplasm, where most
of the VPA remains up to 45 minutes (A). Uptake of VPA is eliminated with membrane
depolarization using FCCP (B). With increasing concentrations of bicarbonate (E-H),
VPA effects (D) become less dramatic, until by 10 mM HCO3 VPA-treated embryos are
indistinguishable from controls (C). Experiments performed by the Williams lab.
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Figure 3.8 Cellular uptake of VPA occurs through a bicarbonate channel.
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3.3 CONCLUSION
In the present work, we clarified the mechanism by which VPA exerts its effects in
Xenopus. We identified the method in which VPA enters the cell, and confirmed that its
activity as an HDAC inhibitor accounted for our observed phenotypes. In the previous
chapter, VPA was used to broadly identify HDAC-dependence of blood development.
Through the comparison of phenotypes resulting from treatment with compounds that
differentially inhibit HDAC isoforms, we identified VPA as a class I HDAC inhibitor, and
hdac3 as the primary target for VPA-induced inhibition of blood development. These
findings were confirmed by morpholino mediated knockdown of hdac3, which
phenocopied VPA treatment in both whole embryos and ectodermal explants. These
data represent the first identification of an explicit function for HDAC in Xenopus.
Moreover, the present work indicates for the first time that hdac3 is indispensible for
primitive hematopoiesis.

3.4 MATERIALS AND METHODS
Embryo manipulations:
See Chapter II;
Oligonucleotide morpholino for hdac3 (GeneTools) 5’ -TGCCATTTCGCTGCCACAGACAGGC3’, was injected at 80ng per embryo. Each injected blastomere received 10 nl of RNA or
morpholino. All injections were made marginally (or in the animal region, for explant experiments)
in each blastomere of 2-cell stage embryos.
Drug treatments for HDAC studies were performed from stage 10 to stage 12 unless otherwise
noted. Final concentrations used in each treatment were as follows: 2mM valproate (Sigma); 100
nM Trichostatin A (Sigma); 2mM Valpromide (gift from Katwijk Chemie B.V.); 250 uM for each
Compound 60 and CI995 ( both were a kind gift from Stephen Haggarty).
Drug treatment for bicarbonate studies were performed at the 16-cell stage (~3 hours post
fertilization) and 2 mM VPA and indicated doses of bicarbonate were administered. Embryos
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were cultured at 21°C until stage 40 or 41 (3 days post fertilization). All experimental conditions
were confirmed at constant pH (7.8).
In-situ hybridization, benzidine staining and immunoblotting:
See Chapter II;
Histone isolation was performed as previously described previously, with little modification
(Gurvich et al., 2004). Briefly, 20 embryos were lysed, acid extracted overnight, and precipitated
with trichloroacetic acid. 1 embryo equivalent was used for immunodetection by anti-H3acK9/14
antibody (Millipore). Immunoblotting was performed as described previously (ref). 10 embryos
were lysed; 0.5 or 1 embryo equivalent was detected with anti-HDAC3 (Cell Signaling) or antiHDAC1/2 (Millipore). 1/10 embryo equivalent was detected with anti-acetylated tubulin antibody
(1igma) or anti-beta tubulin antibody (BD Pharmingen).
RNA quantitation: See Chapter II
Dictyostelium assays:
Dictyostelium gene and protein information was obtained from DictyBase (www.dictybase.org).
Dictyostelium were grown in association with Raoultella planticola or in shaking culture (HL-5
6

medium) at 21˚C. Cells were maintained and harvested in mid-log phase (1-4x10 cells/ml).
3

Subcellular localization of H-VPA (Hartmann Analytic) was performed by taking a 1ml cell
sample at each time point and washing once with KK2. Cellular fractions were obtained by
differential centrifugation as described previously (Williams et al., 1999) and analyzed by liquid
scintillation. Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) was purchased from
Sigma-Aldrich, UK.
In vitro HDAC assays
Recombinant, full-length HDAC protein (BPS Biosciences) was incubated with fluorophore
conjugated substrates. Reactions were performed in assay buffer (50 mM HEPES, 100 mM KCl,
0.001% Tween-20, 0.05% BSA, 200 µM TCEP, pH 7.4) and followed for fluorogenic release of 7amino-4-methylcoumarin from substrate upon deacetylase and trypsin enzymatic activity.
Fluorescence measurements were obtained approximately every five minutes using a multilabel
plate reader and plate-stacker (Envision; Perkin-Elmer). Replicate experimental data from
incubations with inhibitor were normalized to controls. Bradner, J. E.; West, N.; Grachan, M. L.;
Greenberg, E. F.; Haggarty, S. J.; Warnow, T.; Mazitschek, R.Nat. Chem. Biol. 2010, 6, 238-243.
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4. CHAPTER IV: DISCUSSION
In the present work, we have identified hdac3 as a critical component required for
primitive hematopoiesis in Xenopus laevis. Erythropoiesis is blocked when HDAC
function is inhibited by VPA during gastrulation (Chapter 2) and pharmacological studies
with selective HDAC inhibitors indicate that VPA disrupts early Xenopus development
primarily through inhibition of hdac3 (Chapter 3). This was confirmed by morpholino
knockdown of hdac3, which blocks primitive erythropoiesis and causes a morphological
phenotype highly similar to VPA exposure. Finally the mechanism of cellular uptake of
VPA was identified as bicarbonate channels, demonstrated through a genetic screen in
Dictyostelium and additional experiments in Xenopus where progressive increases in
bicarbonate resulted in less severe defects in VPA-treated embryos. These findings
increase our understanding of vertebrate blood development, and provide insight for the
underlying cause teratogenic effects caused by VPA.

4.1 VPA Disrupts Primitive Hematopoiesis in Xenopus
In the present work, VPA, an established HDAC inhibitor, was used to determine
whether HDACs play a role in primitive hematopoiesis (Figure 4.1). Treatment with VPA
during the time that primitive blood is specified, gastrulation, resulted in the absence of
circulating RBCs in tailbud stage embryos (Figure 2.3). In addition to a loss of globin
expression within the VBI, dramatic reductions were also observed in the expression of
mediators of the erythroid transcriptional program including runx1, scl, and gata1.
Despite their clear down-regulation, a small region of expression of each gene was
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Figure 4.1 Model for HDAC3 mediated primitive erythropoiesis. VPA inhibits
HDAC3, which acts downstream of SMAD signals and upstream of gata1,
gata1 gata2 and
runx1 to promote hematopoiesis. Dashed lines show alternate mechanism of VPA
through FGF activation.
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sustained within the anterior-most portion of the VBI following VPA treatment. The
remnant expression of these key erythroid transcription factors was insufficient to permit
normal RBC formation. While it is unclear why these cells were unaffected by VPA
treatment, it is possible that in coordination with their movement during gastrulation, the
anterior-most cells of the VBI are the first exposed to inductive signals that drive
erythroid differentiation, these cells have already been specified by the time VPA has
entered the cells and exerted its inhibitory effect on HDAC function.
Interestingly, inhibition of HDACs by VPA during gastrulation blocks primitive
erythropoiesis without disrupting endothelial or myeloid lineages, which are also derived
from the VBI (Figure 2.7). At neurula stages, runx1 expressing cells comprise a mixed
population of erythroid precursors and hypothesized hemangioblasts, which co-express
myeloid, endothelial and other erythroid markers (Walmsley et al., 2002). With VPA
treatment, a reduction in runx1 expression is observed (Figure 2.6); however it is unclear
in which subpopulation of cells- hemangioblast cells or erythroid precursors- this loss is
occurring. Careful in-situ hybridization studies could determine which of these
populations of cells is affected by HDAC inhibition. Due to the normal development of
endothelial and myeloid lineages in VPA treated embryos, it is most likely that the loss of
runx1 represents fewer erythroid progenitors and that VPA does not interfere with
hemangioblast specification.
In order to determine in what way and on what targets HDACs may function
during primitive hematopoiesis, rescue experiments were conducted in which erythroid
transcription factors were overexpressed in embryos treated with VPA. Overexpression
of runx1 (Figure 2.15) and gata2 (not shown) each partially rescued the blood defects
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induced by VPA, suggesting that HDAC activity is required upstream of these
transcription factors. Since runx1 and gata2 function in complexes with transcription
factors such as scl and gata1 (Mead et al., 2001), experiments overexpressing each
gene in combination with one another may help to identify how these transcription
factors rely on HDAC function during primitive hematopoiesis. Experiments conducted in
ectodermal explants injected with bmp4 mRNA suggest that HDAC activity is required
for hematopoiesis downstream of bmp4 (Figure 2.10), the key inductive signal driving
primitive hematopoiesis (Larsson and Karlsson, 2005).
There is a well established reciprocal antagonism of BMP and FGF signaling in
hematopoiesis, although the mechanism for this is still under investigation (Walmsley et
al., 2008; Xu et al., 1999). Studies in Xenopus neural induction suggest that the two
pathways converge on the downstream effectors of BMP signaling, SMAD proteins,
which are phosphorylated by FGF signaling, resulting in its inhibition and subsequent
degradation (Eivers et al., 2008). However, whether FGF and BMP interact through
SMADs in hematopoiesis is still unknown. Because VPA treatment results in
upregulation of ncam, a neural marker and target of FGF signaling in the dorsal
mesoderm, we next investigated whether the inhibitory effects of VPA on hematopoiesis
were enacted through FGF signaling. Overexpression of fgf4 in Xenopus embryos
resulted in strikingly similar defects to VPA treatment: a reduction in blood (Isaacs et al.,
2007), edema, reduced eye size, and curved tails (data not shown). We also observed
expansion of wnt8 (a downstream target of FGF signaling) (Hong et al., 2008)
expressing cells in VPA treated embryos. While these data suggest a mechanism
whereby HDAC inhibition induces aberrant FGF signaling, we observe no measurable
changes in fgf4 expression with VPA treatment until after blood has been specified
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(Figure 2.14E). However, it is possible that similar phenotypes in VPA treated and fgf4
overexpressing embryos are due to convergence of the two pathways at some point. For
instance, FGF signaling in the mesoderm may repress HDAC expression or activity,
although no such interaction has been reported. Alternatively, a downstream target of
FGF signaling, the protein pv.1, is known to inhibit primitive hematopoiesis (Xu et al.,
1999). This would therefore serve as a promising intersection of HDAC activity and FGF
signaling that may explain the similar phenotypes observed.

4.2 VPA blocks Primitive Hematopoiesis through Inhibition of Hdac3 Activity
Comparison of VPA treated embryos to those treated with a second HDAC
inhibitor, TSA, confirmed that disruption of primitive hematopoiesis is due to inhibition of
HDAC activity by VPA (Figure 3.1). Interestingly, TSA is a class I and II HDAC inhibitor,
but embryos exposed to TSA phenocopy those exposed to VPA, exclusively a class I
inhibitor. This suggests that during early embryogenesis, class II HDACs may have a
limited role or one that overlaps with class I HDACs. This is supported by mouse studies,
in which class I knockout mice die early during development, while mice lacking class II
HDACs typically survive to birth (Haberland et al., 2009b). This is further supported by
the observation in the present work that embryos treated with VAHA, a class II specific
HDAC inhibitor, display no overt developmental defects (Figure 3.3).
Previous work from our group had suggested that VPA inhibits class I and II
HDACs, however these results were based on immunoprecipitation of class II HDACs,
which we now know to associate with class I HDACs (Gurvich et al., 2004). When these
class II HDACs were assayed for sensitivity to VPA, inhibition of the bound class I
HDACs – likely HDAC1 – were misinterpreted as class II inhibition. In the present work,
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the specificity of VPA was revisited in collaboration with the Haggarty lab, where VPA
sensitivity was tested on recombinant HDAC proteins (Figure 3.2). This refined approach
revealed that VPA is in fact solely a class I HDAC inhibitor. This suggests that a class I
HDAC, of which there are four members, is essential for primitive hematopoiesis in
Xenopus.
To identify which HDAC is or are inhibited by VPA to prevent blood development,
we utilized class I specific HDAC inhibitor compounds with overlapping specificities.
Unfortunately, these compounds were not readily taken up into cells, and required
significantly longer exposure times. This precluded examination of a blood phenotype,
and therefore gross anatomic effects were compared instead. Inhibition of hdac1 and
hdac2 did not preclude normal development (Figure 3.4B), while inhibition of hdac1,
hdac2 and hdac3 reproduced the VPA phenotype (Figure 3.4C, D). This suggests one of
two possibilities: first, that hdacs1, 2, and 3 serve redundant roles, and only one of the
three is necessary for normal development or second, that the developmental defects
associated with VPA-treatment are due exclusively to hdac3 inhibition. We find support
for the latter through targeted knockdown experiments using an hdac3 morpholino. The
hdac3 MO phenocopied VPA treatment in whole embryos (Figure 3.6) and ectodermal
explants (Figure 3.7), indicating for the first time a role for hdac3 in primitive
hematopoiesis. Finally, globin expression was partially rescued in hdac3-MO treated
embryos injected with human hdac3 mRNA. The rescue of globin expression was partial
in part due to the inhibitory effects of hdac3 mRNA (Figure 3.6E). This highlights one of
the challenges in our overexpression studies. While it is unclear why, overexpression of
pro-erythroid factors such as runx1 and gata2 can have counterintuitive results; too high
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a concentration of either mRNA results in disrupted primitive hematopoiesis (data not
shown).
It is not surprising that VPA enacts its effects through inhibition of hdac3, given
that the majority of VPA that enters a cell resides in the cytoplasm (Figure 3.8). Hdac3 is
the only class I HDAC that is found not only within the nucleus but within the cytoplasm
as well (Wanczyk et al., 2011). While this would suggest that an interaction of hdac3 with
VPA is possible, it does not exclude the possibility that VPA inhibits hdac1 and hdac2 as
well. Changes in histone acetylation with VPA treatment suggest that, while most VPA is
found in the cytoplasm, enough enters the nucleus – where hdacs1, 2, and 3 can all be
found – to cause global acetylation of histones. The current work does not preclude a
role for hdac1 or hdac2 in primitive hematopoiesis. In fact, recent work in zebrafish has
confirmed the importance of hdac1/2 for primitive hematopoiesis, demonstrating that
nucleosome remodeling and deacetylase (NuRD) complexes, are essential for the
initiation of erythropoiesis (Li et al., 2009). The authors concluded that NuRD complexes
act upstream of scl and gata1. Our work demonstrates that hdac3 is required
downstream of gata1. These two studies are complementary, and suggest a regulatory
network that requires multiple HDACs at different stages during hematopoiesis.
The association of VPA-induced defects with hdac3 is supported by findings in
zebrafish (Farooq et al., 2008), where hdac3-MO also phenocopied VPA treatment. In
their work however, VPA treatment resulted in a liver phenotype that was not observed
in the present work. Nonetheless, consistent with our findings in blood, the liver
phenotype observed in zebrafish was reproduced by hdac3-MO and hdac3 mRNA was
rescued VPA mediated defects. Therefore the association of VPA-induced
developmental defects with impaired hdac3 function appears to be conserved between
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zebrafish and Xenopus. Interestingly, in zebrafish inhibition of hdac1 reproduces some
of the developmental defects observed here for Xenopus with VPA treatment, including
cardiac looping and cranial defects (Pillai et al., 2004). In Xenopus, our current findings
do not indicate whether looping and cranial defects are due to hdac1 or hdac3 inhibition.
A morpholino approach would be valuable for assessing the roles of hdac1 and hdac2 in
Xenopus. However, a knockdown is difficult to accomplish because of gene duplication
in Xenopus, resulting in two copies of each HDAC, and is further complicated by the
presumed redundancy and functional compensation between hdac1 and hdac2
(Montgomery et al., 2007). Were it possible to efficiently knock down hdac1 and hdac2, it
would be insightful to repeat the experiments performed with hdac3-MO to identify
specific developmental defects associated with these two enzymes, and to further
characterize what role they may play during embryogenesis.

4.3 A Unique Role for HDAC3 in Primitive Hematopoiesis
The identification of hdac3 as a critical component driving primitive
hematopoiesis introduces several interesting observations regarding the apparent
specificity of HDACs in early development. VPA treatment specifically inhibited blood
development when applied during gastrulation. Treatment prior to gastrulation resulted in
normal embryos with no observable defects (Figure 2.4). This suggests that prior to
gastrulation, class I HDACs have a limited role in embryogenesis. Despite the many
specification events occurring during gastrulation, VPA treatment affects only blood
development, and other mesodermal structures form normally (Figure 2.9). In other
words, during gastrulation the overall function of class I HDACs appears restricted to
primitive hematopoiesis. Beyond this tissue-specificity, because hdac3MO phenocopies
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VPA (which inhibits hdacs1, 2, and 3) developmental defects so closely, it raises the
question as to what – if any – the functional roles of hdac1 and hdac2 are during
gastrulation.
This is further supported by the dynamic expression profile of hdac3 (Figure 3.5).
Hdac3 expression is highest immediately preceding blood specification, and rapidly
decreases after that. A similar pattern is observed for hdac2. In other words, hdac3 is
present in the embryo uniquely during the time that we know it is necessary for blood
specification, and quickly disappears after that. This is not to say that hdac3 does not
perform other functions during later development and in adulthood. Related to this, the
erythroid transcription factors gata1 and gata2 are suppressed by VPA mediated HDAC
inhibition at stage 12 when blood is being specified (Figure 2.11C, D). Later, at stage 20,
expression of both gata1 and gata2 has returned to normal levels despite VPA
treatment. This suggests that the expression of these transcription factors, which are
required for primitive hematopoiesis, are under the influence of HDAC activity during
gastrulation. These observations all seem to suggest a very specific, defined, and
singular function for hdac3 in the early embryo.
Finally, it is interesting to consider the findings of the present study in the context
of what is currently known or assumed about HDACs. It is generally accepted that
HDACIs regulate proliferation and cell death. However inhibition of HDACs in the
present study did not adversely affect either cell proliferation or apoptosis (Figure 2.8).
Additionally, HDACs are typically thought of as repressors, forming repressor complexes
that deacetylate histones to negatively regulate transcription of target genes.
Consequently, one would expect that inhibition of HDACs would result in gene
activation. However in the present study, gene activation was rarely seen with HDAC
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inhibition, and we instead observe a decrease in expression of several hematopoietic
genes. These apparent inconsistencies are quite interesting and suggest that HDACs
are considerably more complex in their function than has been previously thought.

4.4 Identifying a mechanism for HDAC3 in Primitive Hematopoiesis
Our findings appear to disagree with generally accepted notions that HDACs
serve primarily as repressors of transcription. It is possible that we have not yet identified
the gene or genes that negatively regulate hematopoiesis, and whose expression is ‘derepressed’ upon HDAC inhibition. Alternatively, our findings could be explained by
HDACIs diminishing activity of non-histone proteins necessary for hematopoiesis by
altering their acetylation states. Many of the transcription factors involved in
hematopoiesis can be acetylated to regulate transcriptional activity. Acetylation of
human gata1 has been proposed to regulate chromatin binding and gata1-dependent
transcription (Boyes et al., 1998; Lamonica et al., 2006), and HDAC inhibition in
hematopoietic cell lines causes degradation of gata1 protein due to hyperacetylation
(Hernandez-Hernandez et al., 2006). Thus inhibition of hdac3 could lead to persistent
acetylation and subsequent degradation of gata1 protein, preventing hematopoietic
specification. Indeed a protein-protein interaction of hdac3 with gata1 has been
observed, suggesting that such a mechanism is possible (Watamoto et al., 2003).
However there is currently no evidence on how this interaction regulates gata1
dependent transcriptional activity. Similarly, gata2, runx1 and scl activity is also
regulated through acetylation (Huang et al., 2000; Ozawa et al., 2001; Wang et al.,
2009). Presently, only gata2 has been shown to interact with hdac3, and no specific
HDACs are associated with either runx1 or scl protein (Ozawa et al., 2001). With the
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exception of gata1, there is no evidence suggesting inhibition of HDAC activity could
disrupt the activity of these transcription factors. However they are all appealing
candidates for future studies investigating the mechanism behind hdac3 mediated
hematopoietic defects.

4.5 HDACs and Primitive Hematopoiesis in Mammals
HDACs, including hdac3, play multiple roles in development and in adult tissues
in diverse organisms (Haberland et al., 2009b), but a role for hdac3 in primitive
hematopoiesis has not previously been described. Hdac3 knockout mice die prior to
E9.5 due to defects in gastrulation (Bhaskara et al., 2008; Bhaskara et al.; Montgomery
et al., 2008); early hematopoiesis was not addressed in those publications but may be
difficult to evaluate given the early lethality. We also observe gastrulation defects in
Xenopus embryos injected with high concentrations of the hdac3 morpholino (data not
shown), but with lower doses, embryos gastrulate normally and still demonstrate
markedly reduced blood development. In order to determine whether inhibition of hdac3
function also reveals a role for hdac3 in mammalian primitive hematopoiesis, we
performed experiments in mouse embryos to observe whether VPA obstructs blood
development in this system. Mouse embryos exposed to VPA in vitro demonstrated a
significant reduction of RBCs and erythroid progenitors (Figure 2.16). These findings are
analogous to our observations in Xenopus, and strongly support the importance of
HDACs for mammalian primitive hematopoiesis. While we have not shown directly that
the loss of blood in the mouse is due to VPA mediated inhibition of hdac3, parallels
between the VPA phenotype in mouse and Xenopus suggest that this is likely.
Establishing a direct causal relation between hdac3 and primitive hematopoiesis in
84

mouse is difficult due to early embryonic lethality of the HDAC3-/- mouse. Therefore,
alternative strategies such as application isoform specific HDAC inhibitors like
Compound 60 and CI-994 (Chapter 3) could be used to help elucidate the involvement
of hdac3 in mouse hematopoiesis.

4.6 HDAC mediated teratogenicity
VPA is associated with multiple and potentially devastating birth defects in
humans, including spina bifida and other neural tube closure defects, craniofacial
defects including cleft lip and palate, and defects in limb, cardiac, and genitourinary
development (Jentink et al., 2010); VPA has thus been extensively studied as a model
teratogen in rodents, Xenopus, and zebrafish (Gurvich et al., 2005; Menegola et al.,
1996; Narotsky et al., 1994; Phiel et al., 2001). Prolonged exposure to VPA causes
multiple defects in Xenopus, including defects in anterior development, shortened
anterior-posterior axis, cardiac looping defects, and pigment defects, similar to the
effects of hdac3 depletion (Figures 2.1 and 3.6). Additional studies in zebrafish with
hdac1 mutants and hdac3 knockdown reveal that loss of function of either HDAC
replicates many of the effects observed with long term VPA exposure, including
disruption of heart looping, hematopoiesis, craniofacial development, anterior-posterior
axis formation, and liver and pancreas development (Cunliffe, 2004; Farooq et al., 2008;
Gurvich et al., 2005; Pillai et al., 2004; Yamaguchi et al., 2005). The similar
morphological defects observed in Xenopus and zebrafish with HDAC loss of function,
VPA, and pharmacologically distinct HDAC inhibitors provide compelling support for the
hypothesis that inhibition of class I HDACs is a primary mechanism for VPA-mediated
teratogenesis.
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5. CONCLUSION
In the present work, we identify for the first time a critical role for the enzyme
hdac3 during primitive hematopoiesis in Xenopus laevis, and present findings from
mouse that suggest this role is conserved among mammals as well. Due in large part to
their newly discovered role in cancer, HATs and HDACs have gained considerable
interest in recent years. Despite this, however, to date no precisely defined, tissuespecific function HDACs have been identified in Xenopus, and more generally their
embryologic functions remain poorly understood. Using the HDAC inhibitor valproic acid,
we identified an essential role for HDAC activity in specification of erythroid precursors,
such that when embryos were treated with VPA during gastrulation, the resulting tailbud
stage embryo completely lacked circulating red blood cells.
It is notable that while histone acetylation is an important gene regulatory
mechanism for a number of cellular events, inhibition of all class I HDACs at gastrulation
resulted in a severe, however extremely focused defects in blood, with normal
establishment of the early body plan and of other mesodermal tissues. While it is
generally accepted that HATs function as transcriptional activators and HDACs function
as transcriptional repressors, our findings in the present work suggest that the role of
HDACs may be considerably more complex. Future work will be aimed at identifying the
targets of hdac3 in primitive hematopoiesis, and investigating whether hdac3 also serves
the same purpose in mammalian species. Finally, our work also demonstrates that
specific developmental defects associated with exposure to VPA, a significant teratogen
in humans, arise through inhibition of class I HDACs.
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6. APPENDIX

6.1 Table of Primer Sequences
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6.2 Table of Plasmids for Generating anti
anti-sense Probes
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6.3 Table of Plasmids used to Synthesize mRNA
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